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Abstract 
Transmembrane growth factor receptors mediate signaling through multiple 
intracellular pathways. In breast cancer cells, the type I insulin-like growth factor 
receptor (IGF-IR) has been implicated of tumorigenicity, proliferation, and metastasis. 
However, clinical trials with anti-IGF-IR monoclonal antibodies have generally been 
disappointing, partially due to lack of predictive biomarkers or adaptive compensational 
pathways activated when IGF-IR is blocked. To determine whether IGF-IR inhibition 
could be enhanced by disrupting other pathways, here we sought to investigate novel 
molecular targets downstream of IGF-IR signaling system and evaluate combination 
efficacy in estrogen receptor (ER) positive, basal-like, and endocrine resistant human 
breast cancer cell lines in vitro.  
 
The first part of this dissertation focuses on characterization of the mechanism of 
action and evaluation of therapeutic efficacy of a novel insulin receptor substrate 1 and 2 
(IRS1/2) targeting compound NT157 in multiple breast cancer types. IRS1/2 transduce 
signaling from IGF-IR and insulin receptor (InR) to mediate the IGF effects on breast 
cancer cell biology.  IRS-1 plays a critical role in cancer cell proliferation in ER positive 
breast cancers while IRS-2 is the predominate isoform in many basal-like breast cancers 
and is associated with motility and metastasis.  NT157, a small-molecule tyrphostin, has 
been shown to downregulate IRS proteins in several model systems.  In ER positive and 
basal-like breast cancer cells, NT157 treatment suppressed IRS protein expression in a 
dose dependent manner. NT157 treatment did not affect IGF-I, IGF-II, and insulin 
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induced activation of phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) and 
mitogen-activated protein kinase (MAPK) in the short term, but longer exposure to 
NT157 inhibited the activation of these signaling pathways. The ability of NT157 to 
induce serine phosphorylation of IRS proteins was dependent on MAPK activation. 
Serine phosphorylation resulted in disassociation between IRS proteins and their 
receptors resulting in IRS degradation.  In ER positive breast cancer cells, NT157 also 
resulted in cytoplasmic ERα downregulation likely because of disruption of an IRS-1-
IGF-IR/InR/ERα complex. NT157 decreased S phase fraction after IGF/insulin treatment 
in ER positive breast cancer cells with inhibition of monolayer and anchorage-
independent growth. NT157 downregulation of IRS protein expression also sensitized ER 
positive breast cancer cells to rapamycin. Moreover, NT157 inhibited the growth of 
tamoxifen resistant ER positive breast cancer cells. In basal-like breast cancer cells, 
NT157 repressed the proliferation (G2/M abrogation) and migration through 
downregulation of IRS1/2 protein. Given that both IGF-IR and InR play a role in cancer 
biology, targeting of IRS adaptor proteins may be a more effective strategy to inhibit 
these receptors. 
 
In the second part of this dissertation, we highlight an amino acid transporter – xC- 
to be a novel co-target in addition to IGF-IR targeted therapies in ER positive breast 
cancer cells. IGF-I stimulates growth of normal and malignant cells. Increased uptake of 
amino acids after activation of IGF-IR signaling has been well characterized. xCT 
(SLC7A11) encodes the functional subunit of the heterodimeric plasma membrane 
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transport system xC- critical for the cellular uptake of cystine, generation of glutathione, 
and modulation of cellular redox control. Here, we show that IGF-I induced xCT mRNA, 
protein expression, and function in ER positive breast cancer cell lines in an IRS-1 
dependent manner. IGF-I further controlled cellular redox level through the xC- 
transporter. IGF-I-stimulated monolayer and anchorage-independent growth was 
suppressed by reducing xCT expression or by treating cells with the xC- chemical 
inhibitor sulfasalazine (SASP). Anchorage-independent growth assays showed that 
disruption of xC- function by SASP sensitized cells to anti-IGF-IR inhibitors (monoclonal 
antibody huEM164 and tyrosine kinase inhibitor NVP-AEW-541). The growth 
suppressive effects of SASP were reversed by the ROS scavenger N-acetyl-L-cysteine. 
Thus, IGF-I promotes the proliferation of ER positive breast cancer cells by regulating 
xC- transporter function to protect cancer cells from ROS in an IRS-1 dependent manner. 
Our findings also imply that inhibition of xC- transporter function combined with anti-
IGF-IR agents may have synergistic therapeutic effect. 
 
The third part of this dissertation aims at thoroughly investigating the IGF’s 
regulation on Nuclear factor-erythroid 2-related factor 2 (Nrf2) in ER+ breast cancers and 
evaluating Nrf2 as a target in triple negative / basal-like (TNBC) breast cancers. Nrf2 is a 
key transcriptional activator that mediates cellular antioxidant response by initiating 
expression of various anti-oxidative and anti-inflammation genes. Constitutive 
stabilization of Nrf2 has been observed in many human cancers and confers chemo- and 
radio-resistance of cancer cells. We examined Nrf2 expression and function in a panel of 
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breast cancer cell lines. mRNA expression of Nrf2 was higher in the TNBC/basal-like 
cell lines MDA-MB-231 and MDA-MB 436 compared to immortalized breast epithelial 
cells and other types of breast cancers. In estrogen receptor positive (ER+) breast cancer 
cells MCF-7 and T47D where basal level of Nrf2 were low, IGF signaling system 
regulated Nrf2 expression, nucleus translocation and ARE-binding capability. 
Downregulation of Nrf2 sensitized ER+ cells’ response towards irradiation in the 
presence of IGF-I ligand. shRNA knock-down of Nrf2 in MDA-MB-231 and MDA-MB-
436 TNBC cells showed decreased mRNA expression of multiple Nrf2 regulated anti-
oxidant and pentose phosphate pathway genes, enhanced basal levels of cellular reactive 
oxygen species, impaired mitochondrial function and reduced S phase entry. Cells with 
decreased Nrf2 had reduced cell growth in monolayer, anchorage independent, and 3-
dimensional growth assays. In addition, Nrf2 suppression reduced cell migration. Nrf2 
down-regulated MDA-MB-231 cells also showed increased response towards ionizing 
radiation in clonogenic and soft agar assays. Furthermore, reduced Nrf2 expression 
decreased the number of stem-like (CD44+/CD24-) population in MDA-MB-231 cells 
possibly through xC- transporter regulation. Thus, IGF signaling induces Nrf2 expression 
and function, which suggests Nrf2 could be a therapeutic co-target in combination to anti-
IGF treatment. Nrf2 regulates various aspects of the malignant phenotype in TNBC that 
inhibition of Nrf2 might be a therapeutic option for TNBC. 
 
Taken together, the data in this thesis demonstrate that IGF-IR activation stimulates 
multiple downstream effectors important for breast cancer cell biology. Inhibition of 
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selected downstream signaling molecules alone or in combination with anti-IGF-IR drugs 
is likely to better therapeutic outcomes in breast cancers.  
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Introduction 
Breast cancer is the most common cancer and the second leading cause of cancer 
death among women in the US. In 2015, about 231,840 breast cancer cases will be newly 
diagnosed and about 40,290 women will die from this disease (www.cancer.org). In the 
past decade the death rate from breast cancer is decreasing, even though breast cancer 
incidence remains high. The wider use of adjuvant therapy for operable breast cancer 
partially accounts for this improvement. Targeting the estrogen receptor-α (ERα) has 
proven to be one of the most useful methods to decrease breast cancer death mortality [1].  
Targeting human epidermal growth factor receptor 2 (Her2) with trastuzumab 
(Herceptin®) has also been an important advance [2, 3]. The clinical success of targeting 
receptors critical in breast cancer biology has underlined the importance of identifying 
and understanding the regulatory pathways involved in breast cancer growth and 
metastases. Furthermore, with the awareness of the complexity and heterogeneity of 
breast cancer [4], developing additional targeted therapies is critical to further improve 
breast cancer outcomes. 
 
The insulin-like growth factor/insulin (IGF/insulin) system possesses potent 
mitogenic and pro-migratory properties and has been extensively implicated in many 
malignancies including breast cancer [5-7]. The type I insulin-like growth factor receptor 
(IGF-IR) is a component of the complex IGF/insulin signaling network. IGF-IR has been 
shown to deregulate cell metabolism, enhance transformation, stimulate proliferation, and 
promote metastasis in breast cancer [5, 6, 8-10]. Numerous lines of evidence suggest that 
blockade of the IGF/insulin signaling pathway inhibits growth and metastasis in multiple 
cancer types including breast cancer both in vitro and in vivo [8, 11-14]. Collectively, 
IGF-IR has been viewed as a potentially valuable target for breast cancer treatment. 
 
The IGF/insulin system consists of three ligands, IGF-I, IGF-II, and insulin; six 
ligand-binding proteins, IGFBP 1-6; and 2 half transmembrane tyrosine kinase receptors 
(RTK), half IGF-IR and half insulin receptor (IR), that are capable of forming various 
types of holo or hybrid full receptors (Figure 1.1). These functional receptors are 
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composed of two extracellular α subunits covalently linked to two intracellular β subunits, 
which contain the tyrosine kinase domains. Following ligand binding to the extracellular 
α subunits, the IGF-IR undergoes a conformational change resulting in activation of its 
tyrosine kinase activity and trans-phosphorylation of the intracellular β subunits. The 
activated receptors then recruit and phosphorylate adaptor proteins including insulin 
receptor substrates (IRS 1-6) and Shc. This couples the initial ligand-binding event and 
further triggers multiple downstream signaling pathways, including phosphatidylinositol 
3’-kinase (PI3K) and the mitogen-activated protein kinase (MAPK). These secondary 
messenger molecules result in stimulation of specific cellular functions, such as 
proliferation, apoptosis, metastasis, metabolism, angiogenesis, and drug resistance [15, 
16] (Figure 1.1).   
 
The closely related insulin receptors are expressed as two isoforms, insulin receptor 
A (IR-A) and insulin receptor B (IR-B) with a 12 amino acid difference in exon 11 [17].  
IR-B is the major form expressed in adults and has high affinity for insulin, while IR-A, 
which is abundantly expressed during fetal development and is commonly overexpressed 
in tumors [17], can transmit signals by binding to both insulin and IGF-II [18]. Since 
deregulation of cellular energy metabolism has been considered as an emerging hallmark 
of cancer [19], IR and its related metabolic syndromes have become another major focus 
in the breast cancer research and treatment field. Both obesity and type 2 diabetes 
mellitus could lead to hyperinsulinemia, which has been reported to overactivate insulin 
receptors in normal breast epithelial cells [20] and in neoplastic tissues [21], increase the 
risk of developing breast cancer in patients with metabolic syndromes [22], promote 
metastatic progression, and associate with poor prognosis in breast cancer patients [23].  
 
Strategies targeting the IGF-I/insulin system  
Blockade of ligand binding 
In normal physiology, insulin is produced by pancreatic β-islet cells and arrives at 
target tissues through the blood circulation. For IGFs, the liver is the major producer for 
the circulating IGF-I, but normal tissue and tumor tissue can frequently secrete both IGF-
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I and IGF-II.  Therefore, IGF-I and IGF-II could affect tumor biology via autocrine, 
paracine, and endocrine mechanisms. As mentioned above, IGF-IR and IR require ligand 
binding for receptor activation, thus reducing ligands levels becomes a reasonable and 
practical strategy to control the IGF-I/insulin signaling in neoplastic tissue. In normal 
physiology, reduction of insulin level is not practical because of the resultant metabolic 
effects on glucose control. In contrast, low levels of IGFs appear to be well tolerated in 
humans [24]. Since IGF-I is regulated by the hypothalamic-pituitary axis, via secretion of 
growth hormone, growth hormone-releasing hormone antagonists (e.g. JV-1-38 [25]) 
disrupting this pathway could be used to affect IGF-I levels. In addition, pegvisomant, a 
direct antagonist of the growth hormone receptor, has been developed to treat acromegaly 
and is also able to inhibit IGF-I levels in normal human subjects [26]. 
 
Another approach to reduce the levels of unbound ligands involves the use of 
monoclonal antibodies to neutralize extracellular IGFs. MEDI-573, a monoclonal 
antibody with high binding affinity for both IGFs selectively inhibits the activation of 
both the IGF1R and IR-A signaling pathways in vitro and in mouse models without 
disrupting glucose metabolism mediated by insulin and IR interaction [27]. MEDI-573 is 
now involved in several phase I clinical trials for different types of tumors 
(clinicaltrials.gov, identifier no. NCT01446159, NCT00816361). Another novel IGF 
ligand neutralizing antibody, BI 836845 (Boehringer Ingelheim Pharmaceuticals), was 
recently shown to improve preclinical antitumor efficacy of rapamycin by suppressing 
IGFs’ bioactivity and inhibiting rapamycin-induced PI3K/AKT activation. This drug is 
currently in a phase I clinical trial (NCT01317420).   
 
IGFBPs regulate IGFs’ bioactivity by sequestering the peptides from binding to the 
receptors. Most of the IGFBPs can also act in an IGF-independent fashion. IGFBP3, in 
particular, has been shown to directly associate with cell surface and nuclear receptors 
thereby inducing antiproliferative effects and apoptosis (extensively reviewed in [28]).  
Thus, other approaches to reduce the ligands bioactivity may include recombinant 
IGFBPs, namely IGFBP3 [29, 30].  
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Targeting the receptors 
As noted above, IGF/insulin system consists of multiple receptor tyrosine kinases 
and nearly all of them are targetable by either dominant negative constructs or 
pharmacological approaches. Traditionally, IR has not been considered the primary target 
due to its central role in glucose metabolism. However, accumulated data suggests IR-A 
may play important roles in breast cancer progression and survival [31, 32]. IR-A 
signaling has also been suggested as a possible mechanism of resistance to IGF-IR 
targeted therapies [33, 34]. Thus, developing safe therapies to control IR signaling is 
urgently needed. Indirectly targeting IR-A activation by downregulation of one of its 
ligands, IGF-II, has been shown to inhibit cancer cell growth [34]. It is possible that 
ligand neutralization, as opposed to receptor inhibition, could result in less disruption of 
glucose metabolism.   
 
In the past several years, major effort has been directed toward targeting IGF-IR. 
Anti-IGF-IR monoclonal antibodies have been developed and several trials using such 
antibodies as single agents or in combination with other antitumor drugs are in phase I/II 
clinical trials. The antibodies are designed specifically to bind the α subunit of IGF-IR 
with high affinity, thus they do not directly affect IR-A or IR-B. This class of drugs 
shares similar mechanisms of action by interfering with ligand binding to both holo-IGF-
IR and hybrid receptors [35], and causing receptor endocytosis and subsequent 
degradation in the endosome thereby inhibiting cancer cell proliferation and metastasis 
[36].  
 
Figitumumab (CP-751, 871, Pfizer), a fully human IgG2 α-IGF-IR monoclonal 
antibody, generated enthusiasm in a randomized phase II clinical study (NCT00147537). 
The study showed that combined figitumumab with carboplatin and paclitaxel enhanced 
response rate and prolonged progression-free survival and overall survival in non-small-
cell lung cancer (NSCLC). However, Pfizer discontinued two phase III figitumumab 
clinical trials (NCT00673049, NCT00596830) due to a failure to confirm the promising 
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phase II results and also observed substantial toxicity. Treatment of breast cancer patients 
with an aromatase inhibitor with or without figitumumab was studied but showed no 
benefit for the antibody. AVE1642 (sanofi-aventis), a humanized IgG1 antibody, showed 
promising data in preclinical studies [37, 38] but failed in its phase II clinical trials in 
breast cancer patients (NCT00774878). One reason for the failure might be the lack of 
molecular markers that predict IGF-IR sensitive tumors.  
  
Despite these failures, there are still several currently active trials primarily aimed 
to evaluate IGF-IR antibody as an adjuvant agent to other antitumor drugs in many types 
of cancer. Ganitumab (AMG 479, Amgen), a fully humanized IgG1 antibody, is being 
tested in combination with cytotoxic chemotherapy, mTOR inhibitors, and hormonal 
therapies in various diseases including NSCLC, colorectal, pancreatic, ovarian, and breast 
cancer.  Similar trials have been completed with the fully humanized IgG1 IGF-IR 
antibody cixutumumab (IMC-A12, Imclone). 
 
Dalotuzumab (MK 0646, Merck), another humanized IgG1 antibody with 
promising preliminary profiles [39, 40], is currently being studied with aromatase 
inhibitors and the mTOR antagonist in advanced breast cancer.   
 
The anti-IGF-IR monoclonal antibodies also share a common effect on the 
disruption of normal endocrine feedback systems that might have implications for phase 
III clinical trials. One of the common side effects using the antibodies is disruption of the 
negative feedback of IGF-I on growth hormone secretion by the pituitary. Administration 
of the antibodies results in upregulation of the growth hormone serum levels resulting in 
increased circulating IGF levels, hyperglycemia, and hyperinsulinemia [6]. Since the 
antibodies do not block IR signaling, this could explain the failure to demonstrate clinical 
activity when only IGF-IR signaling is disrupted.  Furthermore, subsequent development 
of refectory tumors in IGF-IR antibody treated patients might be due to both 
hyperinsulinemia [41] and high free IGF [41, 42]. Certainly, activation of IR signaling 
could initiate pro-survival signaling to blunt the effects of cytotoxic chemotherapy. A 
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recent clinical trial for women with ER-positive breast cancer reported combined IGF-IR 
antibody with the aromatase inhibitor exemestane trended toward benefit only in patients 
with normal hemoglobin A1C levels, which is an indicator for insulin resistance. In IGF-
IR antibody clinical trials design, patients with pre-existing insulin resistance may need 
to be excluded or have their hyperinsulinemia better controlled. It would be important to 
state that in preclinical model systems as seen with rodents, the effect of 
hyperinsulinemia is not seen after exposure to IGF1R monoclonal antibodies as these 
antibodies do not generally cross-react with murine IGF1R. Adult rodents also do not 
have significant level of circulating IGF-II [43], thus mouse models might not accurately 
model the human endocrine milieu and the effects of endocrine disruptors designed to 
target human receptors. 
 
Another major class of drugs to target IGF-IR activation is small-molecule tyrosine 
kinase inhibitors (TKI), which compete for the ATP binding site in the catalytic domain 
of the β subunit of IGF-IR and IR. Most TKIs show limited selectivity of IGF-IR over IR 
in vitro or in vivo [44, 45]. The high degree of homology of the intracellular β subunits of 
the IGF-IR and IR may account for this relative lack of selectivity of the TKIs. However, 
this dual targeting might have some benefits given the potential role for IR in cancer.  
Specifically, upregulated levels of insulin after IGF1R monoclonal antibody treatment 
might not have as much effect on the tumor if both IGF1R and IR are blocked by a TKI.  
Studies showed that these TKIs inhibited IGF-IR/IR phosphorylation and AKT activation, 
enhanced apoptosis, decreased in vitro cell proliferation, and tumor suppression in 
xenograft models [40, 46, 47]. A dual IGF-IR/IR dual tyrosine kinase inhibitor BMS-
754807 (BMS) showed better antitumor efficacy in combination with hormonal therapies 
in hormone sensitive breast cancer model systems [47]. BMS-754807 and OSI-906 are 
two promising examples of small molecule inhibitors, being tested in several breast 
cancer clinical trials.  
 
The cyclolignan picropodophyllin (AXL1717 or PPP, Axelar) is reported to 
specifically inhibit IGF-IR specific tyrosine kinase activity, although the exact 
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mechanism is uncertain. The compound reportedly possesses both signal inhibitory 
properties and downregulates IGF-IR in vitro [48]. A phase I trial of this drug has been 
completed showing favorable safety and pharmacokinetics profiles of PPP in patients 
with advanced cancer (NCT01062620). 
 
Other novel approaches to target IGF/insulin system at the receptor level include 
using small interfering RNA (siRNA) and microRNA to suppress IGF-IR expression and 
function.  Recently, an interesting preclinical study showed that 2’-O-methyl modified 
IGF-IR specific siRNA are able to downregulate IGF-IR expression, block IGF-IR 
signaling, and suppress tumor growth in vivo by triggering antitumor immune responses 
[48]. siRNA-based therapies face two major barriers: the delivery of the large and highly 
charged molecules to the targets [49] and the transient effects of the downregulation of 
the target gene. In pre-clinical in vivo studies, the latter could be solved by developing in 
vivo stable and inducible long-term expression of target short hairpin RNA under the 
control of doxycycline, tetracycline, or other dimerizing drugs [50]. Specific microRNAs 
inhibited cancer cell proliferation, motility, invasion, xenograft tumor growth, and 
metastasis in different cancers by downregulation of IGF-IR expression [51, 52].  
Typically these microRNAs have approximately 22 nucleotides and usually have more 
than one target; potential drug candidates need to be carefully examined to exclude off-
target effects before evaluation in clinical trials. Introduction of kinase deficient mutation 
into IGF-IR as a gene transfer strategy could also be an alternative approach to suppress 
IGF-IR signaling pathway and result in tumor suppression [53].  
 
Targeting IGF/insulin downstream signaling pathways 
As noted, PI3K/AKT and Ras-MAPK axis are two well-established intracellular 
signal networks downstream of IGF/insulin signaling. Therefore, several key molecules 
in these pathways might be relevant targets for drug development including mammalian 
target of rapamycin (mTOR), a serine/threonine protein kinase. Activation of mTOR 
upon growth factor stimulation subsequently induces the activation of ribosomal p70 S6 
kinase (S6K1). Phosphorylated eukaryotic initiation factor 4E-binding protein-1 (4EBP1) 
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releases eIF4E, the latter recruits elF4G to form eIF4F complex, which then binds to the 
5’ mRNA cap and initiates cap-dependent mRNA-protein translation, thereby regulating 
cell growth and proliferation (Figure 1.1). Rapamycin and its analogs, everolimus 
(Novartis), temsirolimus (Pfizer) and ridaforolimus (Merck), have been developed to 
inhibit mTOR.  Based on preclinical data using breast cancer cell lines [54-57] and 
mouse tumor models [58], both temsirolimus and everolimus have been approved for 
cancer treatment. Two recently published reports showed that everolimus combined with 
endocrine therapies were of benefit.  In hormone refractory patients, tamoxifen plus 
everolimus resulted in increased clinical benefit compared to tamoxifen alone with 
improved time to progression and overall survival in hormone receptor (HR)-positive, 
human epidermal growth factor receptor (EGFR) 2-negative metastatic breast cancer 
patients [59]. In a similar patient population, everolimus combined with the aromatase 
inhibitor exemestane showed improved progression-free survival in HR positive 
advanced breast cancer patients [60].  
 
These promising clinical studies provide important evidence that anti-ER therapies 
can be combined with anti-signaling strategies. However, some caution is warranted in 
using mTOR inhibitors with the IGF system. Normally, IGF stimulation results in 
activation of S6K1, which negatively regulates adaptor protein insulin receptor substrate-
1 (IRS-1) function by phosphorylation. IRS-1 phosphorylation results in degradation of 
IRS1 protein and suppression of IRS-1 gene expression [61]. mTOR inhibitors disrupt 
this negative feedback loop and enhance IGF/insulin signaling and subsequent 
PI3K/AKT activation [62].   
 
Combination therapy with anti-IGF-IR agents might be needed to address this 
problem and will be discussed later. Beyond mTOR inhibitors, other small molecule 
inhibitors of the downstream pathways, such as PI3K inhibitor LY294002 [63], S6K1 
inhibitor H89 [54], MAPK inhibitor U0126 [54, 64], and dual PI3K/mTOR inhibitor 
NVP-BEZ235 [65] are currently in preclinical and clinical studies. The important 
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translation initiation protein 4EBP1 could also be a potential drug target to terminate 
IGF/insulin signaling induced cap-dependent translation. 
 
Crosstalk and combination therapies  
IGF-IR monoclonal antibodies and mTOR inhibitors 
As noted above, mTOR inhibitors affect the S6K1-IRS1 negative feedback loop 
and result in enhanced PI3K- AKT activation through IGF-IR signaling [66]. If this 
pathway represents a resistance mechanism for the mTOR inhibitors, then co-targeting 
IGF-IR and mTOR might result in enhanced clinical benefit over mTOR inhibitor 
monotherapy.  Studies showed that dual inhibition of IGF-IR and mTOR improved 
antitumor activity in vitro and in breast cancer and other cancer patient tumor samples 
[66, 67]. Currently, Merck is determining the benefits of IGF-IR monoclonal antibody 
(dalotuzumab) and mTOR inhibitor (ridaforolimus) combination therapy in breast cancer 
patients with ER-positive tumors (NCT01220570, NCT01234857). Amgen is evaluating 
the clinical benefits of combining ganitumab with everolimus in patients having 
advanced cancers (NCT01061788, NCT01122199).  The results of these clinical trials are 
expected to reveal the benefits of co-targeting IGF-IR and mTOR. It is worth noting that 
drugs acting as dual inhibitors of PI3K and mTOR, such as NVP-BEZ235, also 
demonstrated improved antitumor efficacy compared to mTOR inhibitors alone [65, 68, 
69].  
 
Targeting IGF-IR/IR and ERα 
Cross talk between IGF/insulin system and estrogen receptor signaling pathway is 
well established [40, 54, 70]. IGF/insulin signaling activates ERα via PI3K/AKT and/or 
MAPK pathways respectively by phosphorylating ERαserine167 and/or ERαalanine118 
[54, 71-73]. Estrogen increases expression of several key genes in the IGF signaling 
pathway including IGF-II [74], IGF-IR, and IRS1 [75], while decreasing expression of 
other genes, such as IGFBP-3 [76] and IGF-IIR [77]. Thus, the overall effect of estrogen 
on the IGF/insulin system is to positively regulate signaling.  
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Acquired resistance to anti-estrogen therapies is an important clinical problem. 
Since ERα may function together with IGF-IR signaling to enhance cell survival [78], 
targeting both pathways may have value.  More recently, microarray data suggest that a 
gene signature co-regulated by IGF-I and estrogen correlated with poor prognosis in 
human breast cancer [64], which also implies dual inhibition of IGF-IR and ER pathway 
may be necessary in certain breast cancer subtypes.   
 
However, the clinical trials using the combination therapy for patients with 
endocrine-resistant breast cancer have been disappointing. In these trials, most women 
had already developed resistance to anti-ER therapies. In most of the reported trials, the 
anti-IGF-IR strategies were tested as the second or third line endocrine therapies.  
 
We have recently shown that tamoxifen-resistant (TamR) cells and tumors lose 
expression of IGF-IR while maintaining IR expression. These findings suggest IGF-IR is 
a poor target in tamoxifen resistant tumors and IR might be an alternative option in 
treating TamR breast cancer [40]. Patients with tamoxifen resistant tumors also show loss 
of IGF-IR at the time of progression on tamoxifen [79]. Thus, endocrine resistant patients 
might not be the best candidates for anti-IGF-IR therapies. However, there are other ways 
to target IGF-IR and IR with small molecule TKIs, ligand neutralizing antibodies, or even 
growth hormone receptor antagonists, so the final word about the clinical relevance of 
these cross talk pathways is not yet settled.  
 
Targeting IGF-IR and human epidermal growth factor receptor (EGFR) 
About 30% of the patients with invasive breast cancers have amplification or 
overexpression of EGFR2 (Her2), which is associated with poor prognosis breast cancer 
[80-82].  Trastuzumab is a recombinant humanized monoclonal antibody that targets the 
extracellular domain of RTK Her2 [83]. Trastuzumab initially showed outstanding anti-
tumor efficacy in patients with Her2 positive breast cancer in combination with cytotoxic 
chemotherapy. However, not all patients benefit from this regimen and in advanced 
breast cancer, resistance develops in about one year [84, 85]. IGF-IR and Her2 are 
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reported to form heterodimers in trastuzumab-resistant breast cells [81]. Further, IGF-I 
was shown to activate Her2 signaling in trastuzumab-resistant breast cancer cells but not 
parental cells. Inhibition of IGF signaling resulted in restoration of trastuzumab 
sensitivity to resistant cells [81, 86, 87]. These preclinical findings led to several clinical 
trials aimed at evaluating the benefits of co-targeting IGF-IR and Her2 in trastuzumab-
resistant breast cancer patients (NCT01479179, NCT00788333, NCT00684983, and 
NCT01111825). 
 
Other combination therapy strategies 
IGF/insulin signaling and chemotherapy:  
Combining either IGF-IR monoclonal antibodies or IGF-IR TKI could enhance 
doxorubicin drug efficacy [37, 88]. We demonstrated that giving cytotoxic chemotherapy 
first or concurrently with IGF-IR inhibitors resulted in a better tumor response. In 
contrast, IGF-IR prior to cytotoxic chemotherapy did not improve the benefits of 
doxorubicin and may represent an interference pathway between cytotoxic chemotherapy 
and IGF-IR inhibitors. These results suggest a combination of IGF-IR blockade and 
chemotherapy works in a sequencing-dependent fashion [37]. 
 
IGF/insulin system therapy and metformin:  
As noted above, IGF-IR blockade is predicted and proven to result in 
compensational upregulation of circulating IGFs and insulin. These effects may cause 
hyperinsulinemia and be clinically manifested as metabolic syndrome or frank type-2 
diabetes [6, 56, 89-91]. Therefore, combining insulin-sensitizing drugs to decrease serum 
levels of insulin with metformin might be necessary to attenuate the metabolic effects of 
the anti-IGF-IR/IR drugs. The I-SPY2 trial of neoadjuvant breast cancer therapy will test 
the therapeutic value of combining ganitumab, metformin and paclitaxel. The metformin 
will help to manage any acquired insulin resistance induced by ganitumab [92]. 
Metformin also reduces reactive oxygen species in mitochondria, which potentially 
would be important to inhibit tumorigenesis independent of the effects on glucose 
metabolism [6, 93]. Thus metformin combined with IGF-IR blockades may not only 
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attenuate the drug-induced hyperglycemia and hyperinsulinemia, but may also exhibit 
antitumor efficacy.  
 
Future Directions 
In order to maximize patient response to the emerging anti-IGF/insulin signaling 
therapies and accelerate developments of these antitumor drugs, the identification of 
therapeutic predictive biomarkers will need great attention. 
 
The ‘figitumumab downfall’ raises an important question: what molecular attributes will 
likely be predictive of tumor dependence on IGF-IR? In these figitumumab clinical trials 
patients were not selected based upon any molecular markers. Microarray analysis has 
been used to determine sarcoma and neuroblastoma cell lines either sensitive or resistant 
to a TKI of IGF1R/IR, (BMS-536924). These data show that the mRNA levels of IGF-I 
and IGF-II highly correlated with cell response to BMS-536924 [94, 95]. Interestingly, 
the mRNA level of IGF1R did not meet the stringent statistical significance threshold to 
serve as an independent predictive biomarker, suggesting hybrid receptor mediated some 
of the IGF-I/IGF-II effects in these cells. Similarly, in a report addressing the sensitivity 
profile of another anti-IGF1R TKI, OSI-906 in colorectal cancer, the level of the 
phosphorylation status of IGF1R alone did not have positive correlation with cell 
sensitivity to OSI-906 [96]. These findings suggest a more complete definition of the IGF 
system signaling components is likely to assist in the clinical evaluation of anti-IGF1R 
therapies.  Distinct receptor composition on the cell surface may influence cancer cell 
biology and predict sensitivity to anti-IGF1R therapy. Many studies have supported the 
important role of holo-IGF1R in cancer [9, 10, 97], yet the function of the IGF1R/IR 
hybrid receptor has not been well studied. The function of hybrid receptor signaling [18, 
34]compared to holo-IGF1R and holo-IR receptors needs further characterization in order 
to serve as predictive biomarkers in breast cancer patients.  
 
In addition, the IGF/insulin downstream signaling effectors may be important to 
predict a patient’s response to the anti-IGF1R therapy. As adaptor molecules are 
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important components to transduce IGF1R signaling, the preferential expression of 
specific IRS isoforms in breast cancer cells has been linked to distinct signal transduction 
pathways and shown to mediate distinct biological behavior [98-101]. Our laboratory 
studied the gene expression profiles of a series of T47D variant cell lines with differential 
IRS adaptor protein expression to develop predictive IGF-I pathway biomarkers in breast 
cancer cells (submitted, Becker et al.). The results have suggested IGF-induced gene 
expression is IRS-dependent and highly conserved. In addition, this previous study has 
revealed several genes regulated specifically by either IRS-1 or IRS-2.    
 
Besides cell surface composition of the receptors and preferential expressions of 
IRS adaptor proteins, other components of the IGF/insulin system may serve as 
predictive biomarkers for therapeutic outcomes and disease prognosis. Pre-treatment 
level of free IGF-I has been shown to predict NSCLC patients’ benefit from IGF-IR 
monoclonal antibody [102]. IGF-IR nuclear staining has been reported to associate with a 
better progression-free survival and overall survival in a small group of soft tissue 
sarcoma patients treated with IGF-IR antibody [103]. A recent report suggested IGFBP5 
expression was associated with resistance to IGF-IR/IR targeted therapy. Furthermore, 
increased IGFBP5/IGFBP4 ratio is associated with decreased sensitivity to IGF-IR/IR 
inhibition and worse prognosis in breast cancer patients [104].  
 
In sum, the IGF/insulin system is complex. Simply targeting one receptor may not 
be sufficient enough to completely inhibit tumor biology. Additional preclinical data are 
needed to unravel the true clinical benefit of the anti-IGF/insulin targeted agents in breast 
cancer patients. This thesis suggesting three novel ways to target the IGF/insulin system: 


















Figure 1.1 Schematic representation of the IGF/insulin system.  
In the extracelluar environment, ligands IGF-I, IGF-II and insulin bind to distinct members of the IGF-IR and IR 
receptor family (as indicated by arrows). These transmemberane tetrameric receptors (three types of holo-receptors and 
three types of hybrid receptors) are composed of two extracelluar α-subunits, which function as binding domains; and 
membrane-spanning β-subunits, which possess tyrosine kinase activity. The bioactivity if IGF-I and IGF-II are 
negatively influenced by IGFBPs and IGF-IIR. Following the ligand binding and receptor activation, the 
phosphorylated adaptor proteins IRS and Shc provide a platform to initiate multiple downstream signaling pathways, 
namely PI3K/Akt and MAPK axis, ultimately influence tumor cell biology.  
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Introduction 
The insulin-like growth factor (IGF)/ insulin signaling pathway has been implicated 
in the proliferation, migration, and survival of many human malignancies[6, 105]. Upon 
ligand binding, the type I IGF receptor (IGF-IR) and insulin receptor (InR) recruit the 
insulin receptor substrate (IRS) adaptor proteins to transduce signals to downstream 
signaling molecules and thereby regulate cellular biology.  In breast cancers, IRS-1 and 
IRS-2 are the two major isoforms that mediate IGF/insulin signaling. The role of IRS-1/2 
proteins in breast malignancies has been well documented: IRS-1 promotes tumor growth 
[100, 101], whereas IRS-2 stimulates motility[99, 101]. 
 
The clinical trials for targeting IGF-IR have generally been disappointing. While 
several factors may account for the limited clinical activity the disruption of endocrine 
homeostasis with resultant hyperinsulinemia could abrogate the effect of only inhibiting 
IGF-IR[106]. Targeting of InR could be difficult due to disruption of glucose 
homeostasis. However, targeting key signaling pathways downstream of both receptors, 
such as the IRS proteins, has appeal and could be another strategy for cancer treatment. 
 
NT157 is a novel small molecule tyrphostin targeting the IRS-1/2 proteins. Its 
efficacy and mechanism of action have been studied in models of melanoma [107] and 
prostate cancer[108]. In our current study, NT157 caused IRS protein degradation by 
inducing serine phosphorylation of IRS and disassociation from IGF-IR and InR in breast 
cancer cells. Treatment NT157 did not affect short-term phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) activation 
induced by IGF-I or insulin. However, prolonged treatment NT157 inhibited PI3K 
activation after prolonged ligand stimulation resulting in cell cycle S phase arrest and 
growth suppression. In estrogen receptor positive (ERα+) breast cancer cell lines where 
IRS-1 is the predominately-activated isoform, the serine phosphorylation of IRS-1 
induced by NT157 compound also promoted the dissociation of ERα from IRS-1-IGF-
IR/InR complex resulting in ERα degradation, cell cycle arrest, and growth inhibition.  In 
basal-like breast cancer cells, NT157 inhibited cell proliferation and was associated with 
  18 
suppression of the mesenchymal markers N-cadherin [109] and vimentin [110] and 
inhibition of ligand-induced migration. Since NT157 inhibited IGF1R and InR signaling, 




NT157 induced IRS protein degradation through serine phosphorylation of IRS-1/2 
in multiple breast cancer cell lines 
 
To evaluate the ability of NT157 to downregulate IRS-1 and IRS-2 protein 
expression breast cancer cell lines were incubated with increasing doses of NT157.  
NT157 reduced IRS1/2 levels while inducing serine phosphorylation of IRS-1/2 (serine 
636/639). IGF-IRβ expression was not affected in ERα+ (Figure 2.1 A top panels) and 
basal-like (Figure 2.1 B left) breast cancer cell lines. NT157 induced IRS protein 
downregulation occurred after 4 hours of drug exposure (Figure 2.8 A). To evaluate the 
mechanism of IRS downregulation and phosphorylation, cells were pre-treated with small 
molecule inhibitors of downstream signaling pathways (Figure 2.1 A bottom panels, B 
right). Only MEK inhibition by UO126 inhibited NT157’s ability to phosphorylate IRS 
proteins.  Inhibition of PI3K (LY294002) or IGF-IR (HuEM164 and BMS-754807) did 
not reverse the serine phosphorylation of IRS by NT157. 
 
NT157 promoted dissociation of IRS-1 and ERα with IGF-IR/InR in breast cancer 
cells resulting in IRS-1 and ERα degradation 
 
Since previous studies showed that IRS-1 and ERα formed a complex in the 
cytosol[111], we examined the effect of NT157 on ERα expression. In ERα+ cell lines, 
NT157 treatment down-regulated total ERα expression (Figure 2.1 A top panels). 
Subcellular fractionation analysis further confirmed that NT157 specifically down-
regulated cytoplasmic ERα (Figure 2.2 A). Whether downregulation of ERα further 
affected gene expression was then examined. After NT157 treatment, in ERα+ breast 
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cancer cell lines, the ERα coding gene ESR1 and its regulated gene IRS-1 [75, 112] and 
CCND1 [111] were significantly suppressed, while IRS-2 expression levels were 
maintained (Figure 2.2 B, Figure 2.4 B). 17β-estradiol (E2) mediated CCND1 and IRS-1 
expression was further analyzed. qRT-PCR results suggested that NT157 treatment 
abrogated E2 stimulation of CCND1 mRNA expression in MCF-7 cells (Figure 2.2 C).  
 
In ERα+ breast cancer tumors and patient-derived cell lines, IRS-1 was positively 
correlated to ESR1 expression [113] (Figure 2.9) suggesting a role for NT157 in 
responses to E2. In basal-like cell lines where ERα was not expressed, IRS-1 mRNA was 
not affected by NT157 (Figure 2.10 B). To prove the mRNA level suppression was due to 
NT157’s effects on ERα, ERα+ breast cancer cells were transfected with both IRS-1 and 
IRS-2 siRNAs. Genetic downregulation of IRS proteins did not affect ERα protein, 
mRNA expression, or ERα regulated genes expressions (Figure 2.10 A) suggesting that 
NT157 resulted in ERα protein degradation by interfering with its interaction with IRS-1. 
 
IRS-1 protein forms complexes with IGF-IR/InR and ERα at the cell membrane 
[111] in normal mammary epithelial cells and breast cancer cell lines[78]. To determine 
if NT157 affected this complex, cell lysates were immunoprecipitated with IGF1R or InR 
antibodies. NT157 promoted the dissociation of IRS-1 from IGF-IR/IR as well as induced 
the dissociation of ERα from the IRS-1-IGF-IR/IR (Figure 2.3 A). The data above 
suggested a novel function of NT157 compound in ERα+ breast cancer cells. 
 
Down-regulation of IRS proteins in ERα+ cancer cells does not affect short-term 
IGF-I treatment-induced signaling transduction 
 
In the presence of IGF-I, NT157 treatment eliminated the tyrosine phosphorylation 
of IRS1/2 (Figure 2.11 A). Interestingly, neither down-regulation of IRS proteins in 
ERα+ cells by NT157 treatment nor siRNA transfection attenuated activation of short-
term IGF-I-induced signaling cascades (PI3K and MAPK) (Figure 2.3 B, 2.11 B). 
Despite this lack of efficacy on signaling, data indicated that NT157 treatment suppressed 
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cyclin D1 and induced p21 protein and mRNA expression in ERα+ breast cancer cell 
lines (Figure 2.4 A and B, and Figure 2.12).  Cyclin D1 is an estrogen regulated gene, 
thus the degradation of ERα induced by NT157 reduced cyclin D1 expression. IGF-I 
stimulated cyclin D1 was abolished by NT157 treatment in ERα+ cells (Figure 2.4 D). 
Down-regulation of IRS proteins by siRNA did not affect IGF-I regulated cyclin D1 
(Figure 2.10 A bottom panel), which indicated that suppression of IRS protein expression 
alone was not sufficient to inhibit IGF-I regulation of cyclin D1. NT157 disruption of the 
complex was required for maximal effect on cell cycle progression. Cell cycle analysis 
also revealed that NT157 treatment caused S phase arrest upon IGF/insulin system ligand 
stimulation (Figure 2.4 C). The unaltered upstream signaling pathway in ERα+ cancer 
cells may due to compensation of other adaptor proteins, such as shc (Figure 2.2 and 2.4 
A). 
 
NT157 inhibited IGF/insulin and 17β-estradiol (E2) induced cell proliferation in 
ERα+ breast cancer cells 
 
To investigate the specificity and toxicity of NT157 towards IRS proteins, 
immortalized breast epithelial cell line MCF10A, MCF-7L, and MCF-7L tamoxifen 
resistant (TamR) cell lines were studied. MCF-7L TamR cells expressed significantly 
lower level of IRS-1 when compared to its parental cell line[40, 114]. The dose-response 
curves showed that MCF-7L cells were significantly more sensitive to NT157 treatment 
(Figure 2.13 A) than TamR cells. Concentrations of NT157 up to 2µM did not affect 
MCF10A cells while this concentration suppressed monolayer growth of MCF-7L cells 
(Figure 2.13 A left). These data indicated that NT157 potently downregulates IRS 
proteins in multiple breast cancer cell lines and growth effects are associated with the 
level of IRS expression.  
 
NT157 growth inhibitory effects in ERα+ breast cancer cell lines were further 
assessed.  Both monolayer and anchorage independent growth experiments showed that 
NT157 abolished IGF/insulin system ligands (IGF-I, IGF-II, and insulin) as well as E2 
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induced monolayer (Figure 2.5 A, 2.13 B) and anchorage independent growth (Figure 2.5 
B). Moreover, parallel signaling experiments revealed that prolonged NT157 treatment 
resulted in suppressed PI3K signaling, down-regulation of cyclin D1 expression, 
increased p21 expression, and enhanced activation of p38MAPK after ligand stimulation 
(Figure 2.5 C). Genetic suppression of IRS1/2 proteins also resulted in partial inhibition 
of ligand-induced growth (Figure 2.14 A) and attenuated PI3K pathway activation upon 
prolonged ligand stimulation but did not affect the cell cycle machinery (Figure 2.14 B). 
These data indicated that IRS proteins play a role in maintaining persistent activation of 
PI3K pathway. NT157 treatment induced ERα degradation and further suppressed ligand-
stimulation of the cell cycle regulatory machinery in addition to IRS protein suppression. 
Therefore, NT157 inhibited ERα+ breast cancer cells by several different mechanisms 
and was more effective than genetic suppression methods. 
 
NT157 effects in two tamoxifen resistant ERα+ breast cancer cell lines – MCF-7L 
TamR and T47D TamR [40, 114] were also evaluated. These cells have reduced IRS-1 
expression due to ERα functional suppression but retained similar expression levels of 
IRS-2 expression.  Monolayer and anchorage independent growth assays both indicated 
that NT157 blocked ligand-induced proliferation in TamR cells (Figure 2.15).  Thus, 
targeting IRS proteins by NT157 may also have therapeutic potential in treating 
endocrine resistant breast cancers. 
 
NT157 compound sensitized ERα+ breast cancer cells to mTOR inhibition 
 
The mammalian target of rapamycin (mTOR) is a downstream effector of PI3K 
signaling. Inhibitors of mTOR are experimentally and clinically proven to have 
therapeutic effects in breast cancer[115, 116]. However, mTOR inhibitors suppress S6K1 
activity. S6K1 functions to phosphorylate IRS proteins at serine sites resulting in IRS 
downregulation. Thus, mTOR inhibition results in disruption of a negative feedback loop 
to enhance levels of IRS expression[117], increase upstream receptor tyrosine kinase 
activation[66], and may result in resistance to this class of drugs. Therefore, NT157 could 
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overcome the consequences of rapamycin upregulation of IRS and might improve cancer 
cell growth inhibition. 
 
NT157 sensitized ERα+ cellular response to rapamycin treatment in both 
monolayer and anchorage independent growth in full media or IGF-I treated conditions 
(Figure 2.6 A and B top panels). Immunoblot data also showed that rapamycin treatment 
alone caused up-regulation of IRS proteins while NT157 suppressed this effect of 
rapamycin on IRS expression (Figure 2.6 B bottom panel). These data implicated that 
NT157 could be combined with rapalogs in the treatment of ERα+ breast cancers to avoid 
monotherapy induced resistance. 
 
NT157 compound inhibited proliferation and migration in basal-like breast cancer 
cells 
 
Basal-like breast cancer patients do not express ER and express lower levels of both 
IRS-1 and IRS-2 when compared to ERα+ breast cancers (Figure 2.9). However, in 
patients with ER- tumors, high levels of IRS-1 mRNA expression are correlated with poor 
prognosis (overall survival, refractory free survival, and distant metastasis free survival) 
(Figure 2.16). In basal-like cell lines, NT157 treatment also inhibited cell growth (Figure 
2.7 A). NT157 did not affect CCND1 but still up-regulated p21 protein and mRNA 
expression (Figure 2.7 B).  In cell cycle analysis, NT157 caused G2/M phase abrogation 
in basal-like cells (Figure 2.7 C), which was distinct from the mechanism found in ERα+ 
breast cancer cells. 
 
In basal breast cancer cell lines, IRS-2 was shown to be the predominant adaptor 
molecule for IGF/insulin signaling and was required for ligand-induced cell motility 
(Figure 2.1 B, 2.7 E)[99, 101, 118]. NT157 also suppressed MDA-MB-231 cells 
migration possibly by affecting epithelial-mesenchymal transition and reversing MDA-
MB-231 mesenchymal morphology through the suppression of IRS-2, N-cadherin and 
vimentin (Figure 2.7 D, F). 
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Discussion 
Preclinical and population data implicated IGF-IR’s critical roles in cancer biology 
and encouraged the development of anti-IGF-IR targeted therapies. However, almost all 
IGF-IR monoclonal antibody (monotherapy or in combination with other therapies) 
clinical trials have failed due to not show clinical benefit in a significant number of 
patients[105, 119]. Because the IGF-IR inhibitors upregulate systemic insulin levels, 
disruption of InR signaling might be necessary to inhibit this highly homologous 
pathway[106]. Our previous work showed that IRS proteins were the predominant 
adaptor proteins downstream of both IGF-IR/InR in breast cancer cells[99, 100] and IGF-
IR/IR required the IRS proteins to transduce signaling as well as mediate biological 
outcomes in breast cancer models[101]. Disruption of IRS proteins might be a better 
strategy to inhibit both receptors’ signaling pathways. NT157 downregulation of IRS 
proteins resulted in dual receptor intracellular signaling inhibition in melanoma[107], 
prostate[108], and breast cancers. 
 
In the current study, we tested NT157’s efficacy and mechanism of action in 
multiple types of breast cancer cells. In the ERα+ breast cancers, we showed that NT157 
induced the serine phosphorylation of IRS proteins, which resulted in the degradation of 
IRS. We also found that NT157 promoted the dissociation of ERα from IRS-IGF-IR/InR 
complex and resulted in ERα degradation (Figure 2.17). The cytoplasmic degradation of 
ERα further resulted in the ESR1-regulated gene suppression and inhibitory effects of the 
S-phase cell cycle regulatory machinery. These findings were unique in ERα+ breast 
cancers. In the tamoxifen-resistant ERα+ breast cancer cells (details described previously 
[40]), NT157 also had inhibitory effects. Dual targeting of upstream signaling pathways 
and ERα might be superior to targeting a single pathway alone. The clinical approval of 
palbociclib and everolimus for treatment of ERα expressing breast cancer demonstrates 
the value of developing inhibitors of these pathways in hormone sensitive and resistant 
cells. These encouraging results suggested that in hormone resistant TamR cancers, 
targeting IRS proteins could be a therapeutic option. 
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Our study showed that rapamycin treated ERα+ breast cancer cells had elevated IRS 
protein expression levels. Co-targeting IRS by NT157 resulted in improved growth 
inhibitory effects. A recent study showed that IGF-IR and IRS-1 were increased in 
crizotinib treated anaplastic lymphoma receptor tyrosine kinase (ALK) fusion protein 
positive lung cancer patients and co-targeting IGF-IR axis with ALK tyrosine kinase 
inhibitor resulted in therapeutic enhancement[120]. Another study demonstrated that 
targeting PI3K in hormone receptor breast tumors resulted in up- regulation of ER 
function, which suggested that the necessity of co-targeting PI3K signaling pathway and 
ER in ER+ breast cancer patients[121]. NT157’s ability to disrupt IGF-IR/IR-IRS-1-ERα 
complex might make it a better drug to overcome hormone resistance. 
 
We also evaluated NT157 in basal-like breast cancer cell lines. To date, basal-like 
cancers are generally not sensitive to targeted therapies. Our previous and current studies 
suggested that IRS proteins might be a target. IRS-1 expression levels served as indicator 
of poor prognosis in basal-like cancers and IRS-2 mediated the IGF-I induced motility in 
basal-like cell lines. NT157 treatment showed both growth and motility inhibitory effects 
in basal-like cells.  This study implicated that targeting IRS protein in breast cancers have 
broad therapeutic spectrum. 
 
Overall, our study emphasized the NT157 therapeutic potential as mono- and 
combination therapy in various breast cancer models. In addition, we, for the first time, 
revealed that NT157 also targeted ERα in ERα+ breast cancer cells. Targeting IRS 
protein could be useful alone or in combination with other therapies in many different 
subtypes of breast cancer. 
 
Materials and Methods 
 
Reagents and antibodies Growth media and supplements were purchased from 
Invitrogen (Grand Island, NY). IGF-I was purchased from GroPep (Adelaide, Australia).  
IGF-II was purchased from Gemini (Woodland, CA). Insulin was purchased from Eli 
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Lilly (Indianapolis, IN). LY294002, U0126, and actin antibody were purchased from 
Sigma-Aldrich (St. Louis, MO). Humanized anti-IGF-IR monoclonal antibody huEM164 
was provided by Immunogen Inc. (Norwood, MA). BMS-754807 was provided by 
Bristol Myers Squibb (New Jersey, Marco Gottardis). Antibodies for phosphorylated 
AKT serine 473, total and phospho-IGF-IR, total and phosphorylated p44/42 (MAPK), 
phospho-p38 MAPK, total and phospho-IRS-1 (serine 636/639), phospho-S6K1, p21, p18, 
CDK2, CDK6, cyclin D1, cyclin D3, and PARP were purchased from Cell Signaling 
Technology (Beverly, MA). The IRS-2, total ERα, IGF-IRα, InRβ antibodies, and protein 
agarose A were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).  
Horseradish peroxidase-conjugated anti-phosphotyrosine (PY-20) was purchased from 
BD Biosciences (San Jose, CA). Anti-rabbit and anti-mouse horseradish peroxidase-
conjugated secondary antibodies were purchased from Pierce (Rockford, IL). 
 
Cell lines and culture MCF-7, T47D, MDA-MB-231, and MDA-MB-468 cells were 
purchased from the ATCC (Manassas, VA) and cultured following ATCC’s instruction.  
Cell line authenticity is verified by STR analysis on an annual basis (Genetics Resources 
Core Facility, Johns Hopkins School of Medicine, Institute of Genetic Medicine).  MCF-
7L cells were kindly provided by C. Kent Osborne (Baylor College of Medicine) and 
maintained in improved MEM Richter’s modification medium (zinc option) 
supplemented with 5% FBS and 11.25 nmol/L insulin. MCF-7L were evaluated by 
comparative genomic hybridization and found to be nearly identical to the MCF-7 cells 
distributed by the ATCC.  MCF-7L TamR and T47D TamR cells were generated as 
described[40]. All cells were grown at 37 °C in a humidified atmosphere containing 5% 
CO2. 
 
Immunoblot Cells were plated at a density of 3 x 105 in 60-mm-diameter. Upon reaching 
80% confluency estimated by microscopy, cells were switched to serum-free medium 
(SFM) for 24 hour to synchronize cell status, after which treatments were added. Treated 
cells were washed twice with ice-cold phosphate buffered saline (PBS) on ice and lysed 
with TNESV lysis buffer of 50 mM Tris-Cl (pH 7.4), 1% Nonidet P-40, 2 mM EDTA 
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(pH 8.0), 100 mM NaCl, 10 mM sodium orthovanadate, 1 mM phenylmethysulforny 
fluoride, and with proteases inhibitor cocktails. Lysates were centrifuged at 21,000 rpm 
for 30 minutes at 4 °C.  Protein concentrations were measured using the bicinchoninic 
acid protein assay reagent kit (Pierce). Cellular protein (80 µg) was resuspended in 5x 
Laemmli loading buffer with 60 mg/ml DTT and was resolved by SDS-PAGE, 




Total cellular lysates (500 µg) were incubated overnight with IGF-IRα or InRβ antibody 
at 4 °C followed by incubation with protein agarose A for 4h at 4 °C. Samples were 
washed three times with TNESV buffer. 5X Laemmli loading buffer was added per 
immunoprecipitated sample and run on an 8% SDS-PAGE gel. 
 
siRNA transfection and cell stimulation Cells were cultured in growth medium to reach 
confluency of  80% then were transfected with 25 nmol/L siRNA (siRNAs SMARTpool 
were purchased from Santa Cruz Biotechnology) using the TransIT-siQUEST 
transfection reagent (Mirus, Madison, WI) according to the manufacturer’s protocol. 48 
hours later, cells were washed twice with PBS and serum starved for another 24 hours in 
SFM followed by treatments as indicated in the figure legends. 
 
Reverse transcription-quantitative real-time polymerase chain reaction Cells were 
plated at a density of 2 x 105 in 6-well-plates in growth media to reach 80% confluency 
then synchronized in SFM for 24 hours followed by treatments indicated in the figure 
legends.  Cellular RNA was isolated using TriPure Reagent according to the 
manufacturer (Roche, Belgium). For quality control and to determine concentration, a 
260:280 ratio assay was conducted on a spectrophotometer.  Forward and reverse primers 
were designed to target the following transcripts: IRS-1 5’-
TCACAGCAGAATGAAGACC-3’ and 5’-CTACTGATGAGGAAGATATGAGG-3’; 
IRS-2 5’-TCGTGAAAGAGTGAAGATCTG-3’ and 5’-TCCAAACACAGTCATTGCT-
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3’; ESR1 5’-CCCAGGGAAGCTACTGTTTG-3’ and 5’-
CTCCACCATGCCCTCTACAC-3’; CCND1 5’-AAACAGATCATCCGCAAACAC-3’ 
and 5’-GGTTCAGGCCTTGCACTG-3’; P21 5’-CAGGGGAGCAGGCTGAAG-3’ and 
5’-GGATTAGGGCTTCCTCTTGG-3’; and RPLPO 5’-
TGCTGATGGGCAAGAACAC-3’ and 5’-GAACACAAAGCCCACATTCC-3’. A total 
of 1 µg of RNA was reverse transcribed using the Transcriptor Reverse Transcriptase Kit, 
and quantitative PCR was conducted using the Universal SYBR Green Kit according to 
the manufacturer’s protocol (Roche) on an Eppendorf (Hamburg, Germany) Mastercycler 
Realplex4 machine.  The relative concentration of mRNA was calculated using cycle 
threshold values that were derived from a standard curve and normalized to ribosomal 
protein, large, PO (RPLPO) as an internal control. 
 
Monolayer growth assay Cells were plated in 24-well-plates at a density of 15,000 cells 
per well, allowed to attach overnight and starved in SFM for 24 hours to synchronize 
cells. After 5 days of treatments, growth was assessed via the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 50 µl of 5 mg/ml MTT solution in 
SFM were added to each well and incubated for 4 hours at 37 °C. Media were aspirated 
and formazan crystals were lysed with 500 µl of solubilization solution (95% 
dimethylsulfoxide + 5% improved minimal essential media). Absorbance was measured 
with a plate reader at 570 nm using a 650 nm differential filter to assess growth. 
 
Anchorage-independent growth A 1 ml layer of 1% Seaplaque-agarose (BioWhittaker, 
Rockland, ME) in 1.5% FBS-containing growth media was solidified into each well of a 
6-well plate. The bottom layer was overlaid with 1 ml of a 1% top agar mixture for 
12,000 cells per well with indicated treatments. All plates were incubated at 37 °C for 14 
days. Colonies was counted on a light microscope with an ocular grid. Five random fields 
were counted per well and only colonies exceeding half of a grid square were scored. 
 
Cell cycle analysis Cells were typsinized, washed twice in ice-cold PBS, and fixed in 
70% ice-cold ethanol -20 °C over night.  Cell cycle analyses were performed on 
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propidium iodide-stained nuclei by using an AccuriTM C6 flow cytometer (BD 
Biosciences, San Jose, CA). Single cells were gated, 10,000 events were collected and 
analyzed by FlowJo (Tree Star Inc., Ashland, OR) software. 
 
Boyden chamber migration assay Cell motility and invasion were measured by a 
modified boyden chamber assay as described previously[99]. Cells were briefly detached 
by trypsin, washed twice with SFM, and then resuspended in SFM with or without 
NT157 compound. Cells (150,000) were placed in the upper chamber of a 10-well 
Boyden chamber apparatus. Upper and lower chambers were separated by a 
polycarbonate polyvinylpyrrolidone–free filter with 8-µm pores. SFM (0.4 mL) with or 
without IGF (5 nmol/L) was placed in the bottom wells of the chamber. After 5 h of 
incubation at 37°C in a humidified atmosphere containing 5% CO2, cells remaining on 
the topside of the filter were removed with cotton swabs. The filter was then removed 
from the chamber and the cells that had migrated to the underside of the filter were fixed 
and stained in HEMA3. The filter was then mounted onto a glass microscope slide and 
cells were counted (in triplicate) in five different areas using a light microscope. 
 
Clinical data set analysis The relative mRNA expression of IRS-1 and IRS-2 in human 
breast tumor samples was determined by searching the Oncomine database (version 4.4.3, 
September 2012 data release[122]. IRS-1 and IRS-2 mRNA expression was queried in 
TCGA breast dataset using reporter A_32_P165472. For prognostic analyses, overall 
survival and distant metastasis-free survival, stratified by expression (all percentiles 
between the lower and upper quartiles were computed, and the best performing threshold 
was used as a cutoff) of the gene of interest (IRS-1: 204686_s_at; IRS-2: 209184_s_at), 
were presented as Kaplan–Meier plots and tested for significance using log-rank 
tests[123]. TCGA BRCA RNASeqV2 and clinical patient data was downloaded on 
7/1/2014. IRS-1, IRS-2 and ESR1 expression values were normalized by the expression of 
the housekeeping gene GAPDH. Pearson correlations and linear regression was perfumed 
using R function cor and lm. 
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Statistical analysis All data except clinical data sets were analyzed with the unpaired 
Student's t test with the use of Excel 2008 (Microsoft, Redmond, WA). A p value of 
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Figure 2.1 NT157 compound induced IRS protein degradation through serine phosphorylation of IRS-1/2 in 
multiple breast cancer cell lines.  
A. Top panels: MCF-7 and T47D cells were serum starved overnight then treated with increasing concentrations of 
NT157 drug for 4 hours. Cellular lysates were separated by SDS-PAGE and indicated protein levels were assessed by 
immunoblotting. Bottom panels: MCF-7 and T47D cells were serum starved overnight then pretreated with huEM164 
(164, 20 µg/ml, 24 hr), BMS-754807 (BMS, 1 nM, 1hr), LY294002 (LY, 10 µM, 1hr), or UO126 (UO, 10 µM, 1hr). 
Protein levels of phospho-serine IRS1/2, phospho-SHC, and actin were determined by immunoblotting. B. Left: MDA-
MB-231 cells were serum starved overnight then treated with increasing concentrations of NT157 drug for 4 hours. 
Protein levels were assessed by immunoblotting. Right: MDA-MB-231 cells were serum starved overnight then 
pretreated with huEM164 (164, 20 µg/ml, 24 hr), BMS-754807 (BMS, 1 nM, 1hr), LY294002 (LY, 10 µM, 1hr), or 
UO126 (UO, 10 µM, 1hr). Protein levels were determined by immunoblotting. 
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Figure 2.2 NT157-induced ERα expression and function suppression.  
A. T47D cells were serum starved overnight then treated with or without NT157 (3 µM) for 4 hours. Cytoplasmic and 
nuclear ERα were extracted and assessed by immunoblotting. B. MCF-7 and T47D cells were serum starved overnight 
then treated with or without 3 µM of NT157 drug for 4 hours. Total RNA was isolated and reverse transcribed. IRS-1, 
IRS-2, and ESR1 levels were analyzed using qRT-PCR. Data were normalized to RPLP0 housekeeper gene. C. MCF-7 
cells were cultured in estrogen depleted growth media for 2 days then serum starved overnight. Cells were pretreated 
with NT157 (3µM) for 4 hours followed by 4 hours of E2 (1 nM) stimulation. Total RNA was isolated and reverse 
transcribed. IRS-1 and CCND1 levels were analyzed by qRT-PCR. Data were normalized to RPLP0 housekeeper gene. 
Data are mean ± SEM; results are representative of at least three independent triplicates experiments. 
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Figure 2.3 NT157 induced dissociation of IGF-IR/IR and IRS-1-ERα complex while not affecting major 
intracellular signaling cascades induced by short term IGF-I treatment.  
A. MCF-7 cells were serum starved overnight then treated with indicated concentrations of NT157 drug for 1 hour. 500 
µg cellular protein was immunoprecipitated with IGF-IRα or IRβ. Protein levels of IRS-1 and ERα were determined by 
immunoblotting. B. MCF-7 cells were 1) serum starved overnight, pretreated with 3 µM of NT157, then induced with 
or without 5nM IGF-I for 10 minutes; 2) transfected by control or IRS1/2 siRNA for 48 hr, starved overnight, then 
stimulated with or without 5 nM IGF-I. Protein levels of IRS-1, IRS-2, phospho-IGF-IR/IR, phospho-AKT, phospho-
S6K1, phospho-MAPK, and actin were assessed by immunoblotting. 
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Figure 2.4 NT157 inhibited cell cycle regulatory machinery.  
MCF-7 and T47D cells were serum starved overnight then treated with indicated concentrations of NT157 for 4 hours. 
A. Protein levels of phospho-SHC, total-SHC, cyclin D1, p21, and actin were determined by immunoblotting. B. Total 
RNA was isolated and reverse transcribed. CCND1 and p21 levels were analyzed using qRT-PCR. Data were 
normalized to RPLP0 housekeeper gene. C. MCF-7 and T47D cells were serum starved overnight, pretreated with or 
without 3 µM NT157, then induced with or without 5 nM IGF-I for 24 hours. Cells were fixed then stained with 
propidum iodide. Cell cycle frequencies were determined by flow cytometry. D. MCF-7 and T47D cells were serum 
starved overnight, pretreated with or without 3 µM NT157 for 4 hours, then stimulated with or without 5 nM IGF-I for 
6 hours. Indicated protein levels were determined by immunoblotting. Data are mean ± SEM; results are representative 
of at least three independent triplicates experiments. 
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Figure 2.5 NT157 inhibited IGF/insulin system ligand and E2 induced monolayer and anchorage independent 
growth in ERα+ breast cancer cells.  
A. MCF-7 and T47D were plated in 24-well plates, serum starved overnight then treated with indicated treatments 
(IGF-I 5nM, IGF-II 10 nM, insulin 10 nM, and E2 1 nM). Monolayer proliferation was evaluated using MTT assay, 
with results displayed as absorbance at 570 nm. B. MCF-7 and T47D cells were serum starved and treated with or 
without NT157 and ligands in 1% FBS in 0.45% agar and overlaid on 0.8% bottom agar. Colony growth in agarose was 
assessed after 14 days. Colonies formed were counted and averaged from 5 individual microscopic fields. Results 
displayed are the average number of colonies in 5 fields of 3 wells. C. MCF-7 and T47D cells were serum starved 
overnight, treated with or without NT157 and ligands for 24 hours.  Indicated protein levels were determined by 
immunoblotting. Data are mean ± SEM; results are representative of at least three independent triplicates experiments. 
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Figure 2.6 NT157 treatment sensitized ERα+ breast cancer cells to rapamycin.  
A. Left panels: MCF-7 and T47D cells were plated then treated with indicated combinations for 5 days. Monolayer 
proliferation was evaluated by MTT assay. Right panels: MCF-7 and T47D cells were plated in 6-well plates treated 
with indicated combinations. Anchorage independent growth was determined by colony formation in agarose after 14 
days. B. Top panels: MCF-7 and T47D cells were serum starved overnight, treated with indicated combinations. 
Formed colonies were counted and analyzed after 14 days. Bottom panel: MCF-7 cells were treated with indicated 
combinations. Protein levels of IRS-1, IRS-2, IGF-IRβ, phospho-AKT, phospho-S6K1, phospho-p38MAPK, and actin 
were determined by immunoblotting. Data are mean ± SEM; results are representative of at least three independent 
triplicates experiments. 
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Figure 2.7 NT157 inhibited proliferation and migration in basal like breast cancer cells.  
A. MDA-MB-231 and MDA-MB-468 cells were plated and treated with or without NT157 in full growth media. 
Proliferation was evaluated after 3 and 5 days by MTT assay. B. MDA-MB-231 and MDA-MB-468 cells were plated 
and treated with indicated dosages of NT157. Top panels: indicated protein levels were determined by immunoblotting. 
Bottom panels: total RNA was isolated and reverse transcribed. Indicated mRNA levels were assessed by qRT-PCR. C. 
MDA-MB-231 cells were treated with or without 5 µM NT157. Cells were fixed then stained with propidum iodide. 
Cell cycle frequencies were determined by flow cytometry. D. MDA-MB-231 cells were plated in 6-well plate and 
treated with with or without 3 µM NT157 for 24 hours. Phase-contrast images for cell morphology were captured by 
Leica microscopy. E. MDA-MB-231 cells were treated with or without 5 µM NT157 and 5 nM IGF-I. Cell migration 
potential was evaluated by boyden chamber assay. F. MDA-MB-231 cells were treated with indicated dosages of 
NT157 for 4 hours. Lysates were separated by SDS-PAGE and indicated protein levels were determined by 
immunoblotting. Data are mean ± SEM; results are representative of at least three independent triplicates experiments. 
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Figure 2.8 NT157-induced IRS protein degradation was specific. 
A. MCF-7 cells were serum starved overnight then treated with 3 µM NT157 for indicated time period. Protein levels 
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Figure 2.9 ESR1 and IRS-1 expression were positively correlated in primary breast cancers and cell lines.  
A. Top panels: expression analysis of IRS-1 and IRS-2 genes in TCGA Breast Cancer subtypes. Left: Box-whisker plot 
of IRS1 expression normalized to the housekeep gene GAPDH in different breast cancer subtypes. Right: Box-whisker 
plots of normalized IRS-1 and IRS-2 expression in ER positive breast cancers. Bottom panel:  scatter plot of ESR1 vs 
IRS-1 in ER positive breast cancers. Straight line shows the best fit with a Pearson correlation factor of 0.3. B. mRNA 
expression of IRS-1 (left) and ESR1 (right) in a panel of breast cancer cell lines were determined by qRT-PCR. Data are 
mean ± SEM; all qRT-PCR results are representative of at least three independent triplicates experiments. 
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Figure 2.10 The suppressive effects of NT157 on cell cycle regulation was through ER degradation.  
A. Top panels: MCF-7 and T47D cells were transfected with 25nM siRNA control or 25 nM siRNA IRS1/2 for 48 
hours. Total RNA was isolated and reverse transcribed. mRNA expressions of IRS-1, IRS-2, ESR1, CCND1, and p21 
were determined by qRT-PCR. Bottom panel: MCF-7 cells were 1) serum starved overnight, pretreated with 3 µM of 
NT157 for 4 hours, then induced with or without 5nM IGF-I for 6 hours; 2) transfected by control or IRS1/2 siRNA for 
48 hr, starved overnight, then stimulated with or without 5 nM IGF-I for 4 hours. Protein levels of phospho-p38MAPK, 
cyclin D1, p21, ERα, and actin were assessed by immunoblotting. B. MDA-MB-231 and MDA-MB-468 cells were 
treated with 3µM NT157 drug for 4 hours. Total RNA was isolated and reverse transcribed. mRNA level of IRS-1 was 
determined by qRT-PCR. Data are mean ± SEM; results are representative of at least three independent triplicates 
experiments. 
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Figure 2.11 Neither NT157 treatment nor genetic down-regulation of IRS1 or IRS2 affected short term IGF-I 
stimulation induced PI3K and MAPK signaling.  
A. MCF-7 and T47D cells were starved overnight, pretreated with indicated dosages of NT157 drug for 4 hours, and 
stimulated with or without 5 nM IGF-I for 10 minutes. Protein levels of IRS-1, py20, phospho-IGF-IR/IR, phospho-
AKT, phospho-MAPK, total MAPK, and actin were determined by immunoblotting. B. MCF-7 and T47D cells were 
transfected with 25 nM siRNA control, siRNA IRS-1, or siRNA IRS-2 for 48 hours. Cells were then serum starved 
overnight and treated with 5 nM IGF-I for 10 minutes. Protein levels of IRS-1, IRS-2, phospho-AKT, phospho-MAPK, 
and actin were determined by immunoblotting. 
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Figure 2.12 NT157 specifically suppressed cyclin D1 and induced p21 in MCF-7 cells.  
MCF-7 cells were starved overnight, pretreated with or without 3µM NT157 drug for 4 hours, then stimulated with or 
without 5 nM IGF-I for 6 hours. Protein levels of IRS-1 cyclin D1, p21 CDK2, cyclin D3, CKD6, p18, and actin were 
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Figure 2.13 NT157 inhibited proliferation in ERα+ breast cancer cells in a dose dependent manner.  
A. Left: MCF-7L and MCF-7L TamR cells were plated in 24 well plates and treated with indicated dosages of NT157 
drug for 5 days. Monolayer proliferation was determined by MTT assay. Right: MCF-7L and MCF-7L TamR cells 
were plated in 6-well plates and treated with indicated dosages of NT157. Anchorage independent growth was 
determined by colonies formation in agarose after 14 days. B. MCF-7 and T47D cells were serum starved overnight 
then treated with indicated treatment combination for 5 days. Monolayer proliferation was measured by MTT assay. 
Data are mean ± SEM; results are representative of at least three independent triplicates experiments. 
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Figure 2.14 Genetic downregulation of IRS1/2 partially suppressed proliferation and prolonged IGF-I induced 
PI3K activation in ERα+ breast cancer cells.  
A. MCF-7 and T47D cells were transfected with 25 nM siRNA control or 25 nM siRNA IRS1/2 for 48 hours. Cells 
were serum starved overnight then plated in 6-well plates and treated with IGF-I (5 nM), IGF-II (10 nM), insulin (10 
nM), and E2 (1 nM). Anchorage independent growth was determined by colonies formation in agarose after 14 days. B. 
MCF-7 cells were transfected with 25 nM siRNA control or 25 nM siRNA IRS1/2 for 48 hours. Cells were starved 
overnight then plated in 6-well plates and treated with IGF-I (5 nM), IGF-II (10 nM), insulin (10 nM), and E2 (1 nM) 
for 24 hours. Protein levels of IRS-1, IRS-2, phospho-AKT, cyclin D1, p21, and actin were determined by 
immunoblotting. Data are mean ± SEM; results are representative of at least three independent triplicates experiments. 
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Figure 2.15 NT157 inhibited ligand induced proliferation in tamoxifen resistant ERα+ breast cancer cells.  
MCF-7 TamR and T47D TamR cells were 1) serum starved overnight then treated with indicated combinations. 
Monolayer proliferation was assessed by MTT assay after 5 days (left panels). 2) Starved overnight then treated with 
indicated combinations. Anchorage independent growth was determined by colonies formation in agarose after 14 days 
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Figure 2.16 IRS-1 expression had prognostic value in ER negative breast cancers.  
Kaplan–Meier plots of overall survival (OS, top panel), refractory free survival (RFS, middle panel), and distant 
metastatic free survival (DMFS, bottom panel) of patients with ER negative breast cancer with high or low expression 
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Figure 2.17 Model for the inhibitory effects of NT157 on IRS-1 and ERα in ER+ human breast cancer cells. 
A. Under normal condition, IGF-IR signals through the IRS-1/2-PI3K axis, inducing cellular proliferation. B. NT157 
initially binds to an allosteric site on IGF-IRβ subunit and induces a conformational change, leading to the dissociation 
of IRS-1/ERα complex from the receptor. Compensational hyper-activated MAPK mediates cytoplasmic extensive 
serine-phosphorylation of IRS-1 protein. C. Serine-phosphorylated IRS-1/ERα complex is targeted for degradation by 
the proteasome and IGF ligand induced PI3K signaling becomes severely impaired.     
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Introduction 
The insulin like growth factor [61] signaling pathway stimulates growth and 
metastasis in many types of cancer [6, 124]. Ligand dependent activation of the type I 
IGF receptor (IGF-IR) results in recruitment of the insulin receptor substrate (IRS) 
adaptor molecules to transduce signals to downstream signaling cascades and ultimately 
regulate cell behavior. In breast cancer cells, IRS-1 and IRS-2 are the two primary 
adaptor proteins that regulate IGF-IR signaling [125].  In model systems, IRS-1 mainly 
promotes cell proliferation [100, 101], while IRS-2 stimulates cell motility [99, 101].   
 
The clinical results of anti-IGF-IR monoclonal antibody trials in breast cancer have 
been disappointing [126]. Given that breast cancer is highly heterogeneous, there is an 
urgent need to identify predictive biomarkers [119, 127] that correlate with IGF-IR 
driven tumors and to characterize additional molecular targets that may synergize with 
anti-IGF-IR therapy. To identify potential biomarkers, our laboratory characterized the 
gene expression profiles of T47D variant cell lines with differential IRS protein 
expression [101] upon IGF-I stimulation (Becker et al, submitted). SLC7A11 mRNA 
expression was upregulated by IGF-I in an IRS-1 specific manner.   
 
SLC7A11 (or xCT) encodes the functional subunit of cystine-glutamate exchange 
transporter: xC-. xC- transporter mediates the uptake of extracellular L-cystine in 
exchange for L-glutamate. The cell membrane expression of xC- transporter is essential 
for uptake of extracellular cystine to generate intracellular cysteine to maintain 
intracellular glutathione (GSH) levels [128]. GSH controls the intracellular redox state 
[128, 129] protecting cells from multiple sources of damage including chemical, 
radiological, and direct reactive oxygen species (ROS) [130] mediated damage. The roles 
of ROS in cancer are complex due to the heterogeneity of downstream signaling cascades 
activated in response to their generation [131, 132]. Continuous exposure to endogenous 
or exogenous ROS stress results in some cancer cells undergoing apoptosis or growth 
arrest [133]. Other cells can develop redox adaptive mechanisms [134] to prevent 
apoptosis and also increase genomic instability [135], promote malignant transformation, 
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metastasis [136], and contribute to drug resistance [137]. Recent studies reported that 
xCT deficiency sensitizes malignant cells’ response to oxidative stress [133, 138] and 
inhibits cancer cell growth [128] and metastasis [139]. The expression level of xCT 
predicts chemosensitivity to multiple drugs [140], and combining the xCT chemical 
inhibitor sulfasalazine (SASP) with a HSP90 inhibitor celastrol shows synergistic anti-
cancer effects [141].   
 
This study determined the role for IGF-I stimulation of breast cancer cells in the 
generation of intracellular ROS through the regulation of xCT expression and function.  
Co-targeting xC- transporter with anti-IGF-IR therapy was explored as a way to increase 
the efficacy of targeting both pathways. We found that IGF-I stimulated xC- expression in 
an IRS-1 dependent manner. IGF-I also regulated cellular redox status partially through 




IGF-I stimulated SCL7A11 (xCT) mRNA expression in an IRS-1 dependent manner 
in estrogen receptor positive luminal but not in basal-like breast cancer cells 
T47D-YA cells express neither IRS-1 nor IRS-2 [130]. We created T47D-YA cells 
that stably expressed either IRS-1 or IRS-2 cDNA [101]. T47D-YA, T47D-YA IRS-1 
expressing cells (T47D-YA-IRS-1), and T47D-YA IRS-2 expressing cells (T47D-YA-
IRS-2) were used to generate IRS isoform specific gene profiling upon IGF-I stimulation 
(Becker et al, submitted). SLC7A11 (xCT) was one of the genes regulated by IGF-I only 
in T47D-YA-IRS-1 cells. To confirm the gene array result, quantitative reverse transcript 
PCR was performed using primers specific to xCT. The result was consistent with gene 
array data, after 4 hours of IGF-I exposure, xCT mRNA expression was significantly 
induced only in the T47D-YA-IRS-1 cells (Figure 3.1 A).   
 
We next examined the mRNA expression of xCT upon IGF-I stimulation in two 
classes of human breast cancer cells: three estrogen receptor (ER) positive breast cancer 
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cell lines: MCF-7, T47D, and ZR-75-1, where IRS-1 mRNA expression was higher than 
in the three ER-negative breast cancer cell lines: MDA-MB-231, BT549, and HS578T, 
where IRS-2 was the predominant isoform expressed (Figure 3.1 B left panel). IRS-1 and 
-2 protein expression was examined in four of the cell lines (Figure 3.1 C) to confirm the 
mRNA expression levels. In the three ER positive cell lines, xCT mRNA expression was 
significantly upregulated by IGF-I, while no regulation was observed in the ER-negative 
cells (Figure 3.1 B right panel) although the basal expression of xCT mRNA was 
significantly higher. Since ER regulates IRS-1 expression [75], we further investigated 
regulation of xCT in MCF-7L cells and MCF-7L selected for resistance to tamoxifen 
(TamR) cells as previously described [40]. TamR cells expressed lower levels of IRS-1 
(Figure 3.1 D left panels) and IGF-IR while maintaining insulin receptor levels [40]. IGF-
I treatment stimulated xCT mRNA and protein expression in MCF-7L parental cells but 
not in the MCF-7L TamR cells. In parental cells, IGF-II and insulin induced xCT mRNA 
and protein expression while in TamR cells none of the ligands stimulated expression of 
xCT (Figure 3.1 D right panels) above their higher basal levels. This suggested that 
without sufficient IRS-1 expression there is little effect on xCT expression despite 
functional insulin receptor signaling.   
 
To evaluate the relevance of xCT expression in human primary breast cancers, we 
evaluated its expression in The Cancer Genome Atlas (TCGA) database. We found that 
the xCT relative mRNA expression in invasive ductal breast cancer (IDBC) samples was 
significantly higher than that in normal breast tissue. ER positive IDBC expressed lower 
levels of xCT gene compared to ER negative or triple negative IDBC (Figure 3.2 A). We 
next utilized a large public microarray database to evaluate the prognostic relevance of 
xCT in breast cancer patients [123]. We found that high xCT expression significantly 
correlated with poor overall survival (OS) and distant metastasis free survival (DMFS) in 
estrogen receptor positive patients (Figure 3.2 B). These findings from primary breast 
cancer specimens were consistent with our laboratory observations. The results implied 
that xCT expression and function might link to outcome and expression levels varied 
among the intrinsic subtypes of breast cancer.   
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To further confirm the role of IRS-1 in IGF-I regulation of xCT expression, either 
control or IRS-1 specific siRNAs (Figure 3.7) were transfected into ER positive cells 
(Figure 3.3 A upper panels, 3.8 A). xCT mRNA expression and protein expression in 
MCF-7, T47D, and ZR-75-1 were induced by IGF-I only when IRS-1 was expressed at 
normal levels (Figure 3.3 A lower panels, 3.8 B). Expression of xCT protein was seen 
after 24 hour of IGF-I stimulation likely due to a requirement for protein synthesis. These 
results suggested that IGF-I stimulated xCT expression in an IRS-1 dependent manner in 
ER positive breast cancer cells.   
 
We next evaluated potential downstream signaling pathway required for IGF-I 
regulated xCT expression. MCF-7 cells were treated with anti-IGF-IR monoclonal 
antibody, huEM164, IGF-IR/insulin receptor tyrosine kinase inhibitor AEW-541, PI3K 
pathway inhibitor LY294002, or MEK inhibitor U01026 (Figure 3.3 B, 3.9). IGF-I 
regulated xCT mRNA expression via IGF-IR was dependent on PI3K pathway signaling 
but not MAPK.  
 
IGF-I stimulated xC- transporter function  
To investigate whether xC- function was affected by IGF-I stimulation, two direct 
functional assays were performed to measure the intracellular level of reduced GSH and 
the extracellular level of glutamic acid in three ER positive breast cancer cell lines and 
MDA-MB-231 cells. After 24 hours of IGF-I exposure, significant induction of both 
extracellular glutamic acid levels and intracellular reduced GSH concentrations in MCF-7 
and T47D cells was observed but not in MDA-MB-231 (Figure 3.4 A, B, C).   
 
To demonstrate that these effects were mediated by xCT, we used sulfasalzasine 
(SASP) an inhibitor of xC- function. Cells treated with 0.1 mM SASP (Figure 3.10 A, B) 
[128, 133, 141], showed depletion of intracellular GSH and diminished IGF-I regulated 
GSH levels (Figure 4B). GSH production requires gamma-glutamylcysteine synthetase 
function to ligate cysteine with glutamate.  Buthionine sulfoximine (BSO) [142] inhibits 
this ligation and Figure 3.4 B shows BSO had similar effects to SASP. Taken together, 
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these data show that IGF-I regulation of xC- transporter function results in the import of 
cystine to increase the intracellular reduced GSH levels via an IRS-1 dependent manner 
in ER positive breast cancer cells.  In the ER-negative breast cancer cell line, MDA-MB-
231, high basal extracellular levels of glutamic acid were consistent with the expression 
of xCT in ER-negative primary breast cancers (Figure 3.2 A).   
 
IGF-I regulated cellular redox status via xC- transporter  
Reduced GSH is a major cellular antioxidant molecule controlling cellular redox 
balance.  We next examined whether IGF-I induced intracellular GSH level might further 
regulate cellular ROS level in cancer cells. We either irradiated [143] or treated cells with 
mitomycin C to induce intracellular ROS production. A ROS-sensitive fluorescent probe 
2’,7’-dichlorofluorescein diacetate (DCFH-DA) was used to detect cellular ROS.10 gray 
irradiation (Figure S5 A) or 0.1 µg/ml mitomycin C (Figure 3.11 B) significantly 
increased the intracellular ROS levels. The irradiation induced ROS was reduced by 
treating cells with ROS scavenger N-acetyl cysteine (NAC) [144] (Figure 3.5 C right 
panel, 3.10 E right panel). A ROS insensitive probe 5-(and-6)-carboxy-2’,7’-
dichlorofluorescein diacetate (carboxy-DCFDA) was used as assay control (Figure 3.5 C 
right panel). IGF-I treatment blunted the response to ROS production in MCF-7 and 
T47D (Figure 3.5 A, 3.11 A, B) but not in the basal-like MDA-MB-231 cells (Figure 3.11 
A). The IGF-I-mediated reduction of ROS was diminished (Figure 3.5A, 3.11 A) or 
partially attenuated (Figure 3.4 A right panel, 3.11 B) when cells had been pretreated 
with 0.1 mM SASP. Since xCT expression and function were higher in basal like breast 
cancer cells (Figure 3.1 B right panel, 3.2 A, 3.4 A) than in ER positive MCF-7 cells, the 
basal ROS levels in MDA-MB-231 cells were lower than in MCF-7 (Figure 3.11 A).   
 
IGF-I treatment markedly reduced the phosphorylated form of p38MAPK, a major 
effecter of ROS [131, 145], in MCF-7 and T47D cells. Consistent with the results 
obtained from direct ROS measurement experiments, pretreatment of ER positive cells 
with SASP, attenuated phosphorylation of p38MAPK after IGF-I treatment (Figure 3.5 B, 
3.11 B).   
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Thus, our results suggested that IGF-I reduced cellular redox level specifically, but 
not completely, by stimulating the expression and function of xC- transporter in ER 
positive breast cancer cells. We also found that IGF-I-induced ROS reduction was 
mediated by the IGF-IR/PI3K signaling axis as pathway inhibitors (huEM164, LY 
294002, and AEW-541) decreased IGF-I’s ability to reduce ROS generation (Figure 3.5 
C left panel).   
 
In addition to the findings above, anchorage independent growth assays showed 
that SASP significantly sensitized MCF-7 cells response to both irradiation and 
mitomycin C treatments in serum depleting condition, which was reversed by treating 
cells with NAC (Figure 3.5 D). We further verified that BSO had similar effects as SASP 
did (Figure 3.14 A), which was partially over-tuned by adding NAC. Our data implied 
that SASP could enhance response to ROS inducing therapies by lowering intracellular 
GSH level. 
 
Disruption xC- transporter function suppressed IGF-I-induced monolayer and 
anchorage independent growth 
Increased ROS levels have been reported to arrest growth or even cause apoptosis 
in cancer cells which lack oxidative adaptive mechanisms [131]. MCF-7 cells have 
relatively high basal levels of ROS under serum depleting condition (Figure 3.11 A), 
which resulted in partial growth arrest (Figure 3.6 A, B, Table 3.1). IGF-I induced MCF-
7 cell proliferation might be mediated by stimulating xC- transporter function to increase 
cellular GSH level to protect cells from ROS. To test this hypothesis, we either pretreated 
MCF-7 cells with SASP to disrupt xC- transporter function or stably infected xCT-
specific shRNA (Figure 3.12) to downregulate its expression level and performed 
monolayer growth assays. We found that 0.1 mM SASP inhibited the function of xC- 
transporter without significant cytotoxicity in MCF-7 (Figure 3.10 A). Both chemical 
inhibition and genetic downregulation of xCT expression significantly suppressed IGF-I-
induced monolayer growth (Figure 3.6 A, B). SASP effects were reversed by adding 
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NAC (Figure 3.6 A). Cell cycle flow cytometry analysis showed that IGF-I stimulated 
cell S phase frequency was partially repressed when xC- transport was disrupted, which 
could be rescued by NAC (Table 3.1). Anchorage independent growth assays in MCF-7 
cells showed similar results (Figure 3.6 C). Parallel sets of experiments were done by 
treating cells with BSO instead of SASP to directly investigate the involvement of 
cellular GSH in these observations (Figure 3.14 B, C) with similar results. These data 
indicated that IGF-I stimulates MCF-7 cell growth partially by regulation of xC- 
transporters to control cellular GSH and redox levels.   
 
Disruption of xC- transporter sensitized ER positive breast cancer cells to anti-IGF-
IR therapy. 
SASP treated MCF-7 cells showed significant intracellular GSH depletion resulting 
in elevated ROS and phospho-p38MAPK (Figure 3.5 A-C). Anti-IGF-IR therapy such as 
huEM164 and AEW-541 both diminished IGF-I regulation of cellular ROS (Figure 3.5 C) 
and p38MAPK activation (Figure 3.9) while increasing the basal p38MAPK activity in MCF-
7 cells (Figure 3.9). Thus, anti-IGF-IR drugs with xCT inhibition to improve growth 
suppression. 
 
In anchorage independent growth assays, MCF-7 cells were treated with 1 µg/ml 
huEM164 or 0.1 µM AEW-541. These lower drug doses were unable to suppress IGF-I 
stimulated anchorage independent growth. However, when the IGF-IR targeted therapies 
were combined with SASP, IGF-I stimulated colony formation was completely 
(huEM164) or partially (AEW-541) inhibited in the MCF-7 cells, which was reversed by 
treating cells with NAC (Figure 3.6 C). Notably, SASP enhanced the growth inhibition of 
anti-IGF-IR drugs at lower concentrations of these anti-IGF drugs than normally required 
(normally 20 µg/ml huEM164, 0.3 µM AEW-541) for maximal inhibition of signaling 
and growth [40]. Similar results were observed by using BSO instead of SASP (Figure 
3.14 C).  Thus, the biological effects of IGF-IR inhibition could be enhanced by 
disrupting xCT effects while using lower doses of the anti-IGF-IR drugs. 
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Discussion 
It is well known that cellular ROS causes genome instability and mutation to 
stimulate tumorigenesis and increase resistance to therapy. Our data revealed that IGF-I 
signaling increases xC- transporter expression and function in IRS-1 activated ER 
positive to affect cellular redox status and promote proliferation. We also further found 
that stimulation MCF-7 cells with IGF-II or insulin both induced xCT mRNA expression 
(Figure 3.13) implying a similar role for insulin receptor acting through IRS-1. These 
data imply that ER positive breast cancer cells require activated IRS-1 signaling to 
overcome oxidative stress. In contrast, the high basal levels of xCT in ER-independent 
breast cancer cells might have mobilized a set of ROS adaptive mechanisms independent 
of the growth factor/IRS-1 signaling.   
 
It has been recently reported that CD44 variant stabilizes cell surface xCT 
expression [133]. Given that MDA-MB-231 cells are CD44 positive and MCF-7 cells are 
CD44 negative [146], we confirmed that the basal expression and function of xCT was 
significantly higher in MDA-MB-231 cells than in MCF-7 cells (Figure 3.1 B right panel, 
3.4 A). MCF-7 cells expressed little amount of CD44 variant, and none of the IGF 
ligands (IGF-I, IGF-II, insulin) regulated CD44v mRNA expression (Figure 3.13) 
indicating that the xCT regulation of IGF-I might be independent of CD44 variant.  
 
Although in our study the expression and function of xC- is not regulated by IGF-I 
in MDA-MB-231 cells, we still found that low concentration of SASP (0.1 mM) 
treatment depleted the cellular GSH level; genetically downregulation of xCT or SASP 
treatment also decreased the basal proliferation and migration in MDA-MB-231 cells 
(Figure 3.15 A, B). A recent study showed that xC- transporters are commonly expressed 
in triple negative breast cancer cells. Targeting xC- transporters might yield another 
therapeutic opportunity for the triple negative breast cancers as well [147]. Our data also 
suggested that xC- targeting could have a role in ER-positive breast cancer cells. 
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We observed that down-regulation of IRS-1 by siRNA resulted in a significant 
increase of basal xCT protein expression (Figure 3.3 A lower right panel).  Consistently, 
in our experiments, we also observed that the basal xCT expression in MCF-7L TamR 
was higher than that in MCF-7L parental cells (Figure 3.1 D lower right panel). We 
further examined the xCT protein expression in T47D-YA and T47D-YA-IRS-1 cells and 
found that T47D-YA cells expressed significantly more xCT protein than T47D-YA-IRS-
1 cells did (Figure 3.15 C). In patient specimens, ER expression tended to negatively 
correlated with xCT expression while positively correlated with IRS-1 expression in 
TCGA breast cancer database. Given the development of new anti-IRS-1 targeted 
therapies [148], our data suggest that IRS-1 targeting might have adverse effects on ROS 
status.  Further investigation is needed to understand the potential role of IRS-1 protein 
expression in regulating xCT expression levels.  
 
In this study, we inhibited xCT function with SASP and also used the potent 
glutathione inhibitor BSO to examine the effects of GSH levels on breast cancer growth. 
(Figure 3.14).  Both compounds were effective inhibitors highlighting the important role 
of glutathione in breast cancer cells.   
 
Identification of predictive biomarkers to identify patient populations appropriate 
for treatment with targeted therapies would improve patient benefit. In addition, 
identification of key targets in a pathway could result in rational combination therapies.  
While anti-IGF-IR therapy has not yet proven to be of benefit in unselected patients, it is 
possible that biomarkers, such as IRS-1, might be used to identify IGF-IR driven tumors.  
Inhibition of xC- transporter has been reported to have tumor growth inhibitory effects in 
several tumor models including triple negative breast cancers, where xCT expression 
levels are high [128, 133, 141, 147]. Our findings further suggested that xC- transporter 
could be a promising predictive biomarker (Figure 3.2 B) and therapeutic target to benefit 
a much larger population – ER positive breast cancer patients. Both clinic breast cancer 
patients’ data (Figure 3.2 A) and cell culture qPCR data (Figure 3.1 B left panel) showed 
that the basal expression of xCT mRNA is lower than basal like breast cancers. However, 
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our study suggests that IGF-I, IGF-II, and insulin could stimulate xCT expression in the 
ER positive breast cancers through IRS-1 to promote growth. ER positive patients with 
higher circulating IGF-I, IGF-II, or hyperinsulinemia may have higher expression of xCT 
and more aggressive tumors. Our laboratory previously accomplished several studies 
confirmed that anti-IGF-IR monoclonal antibody suppressed ER positive breast cancer 
growth in mouse model [40, 149]. Targeting IGF-IR together with inhibiting xC- 
transporter function might have better therapeutic outcome with lower dosage and less 
side effects than mono-therapy in ER positive breast cancer patients with high circulating 
IGFs or hyperinsulinemia. These hypotheses require further investigations in patients’ 
data set or animal models.  
 
Besides directly inhibition of xC- transporter, recently a promising novel positron 
emission tomography tracer, (4S)-4-(3-[18F]fluoropropyl)-L-glutamate, specifically for 
imaging xC- transporter activity has been proved to have high cancer detection rate in 
rodents [150] and in clinic trial of patients with non-small cell lung cancer and metastasis 
or invasive breast cancer [151]. This imaging technique also would offer clinicians a 
convenient way to monitor malignant cells’ adaptation to oxidative stress in vivo.  
Besides, our findings also implied that co-targeting IGF-IR with xC- transporter might 
reduce the dosage of anti-IGF-IR agents and attenuate potential side effects. Coupling 
chemotherapy or radiotherapy with xC- inhibitor might also achieve synergic therapeutic 
effect.   
 
In conclusion, our study reveals that IGF-I regulates oxidative stress and thereby 
promotes proliferation by stimulating xC- transporter function in an IRS-1 dependent 
mechanism.  xC- transporter expression level could be a promising biomarker to indicate 
tumor metabolic status to oxidative stress.  xC- transporter could be also be a target to 
enhance anti-IGF-IR therapy, chemotherapy, and radiotherapy in multiple subtypes of 
breast cancer.   
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Materials and Methods 
 
Reagents and antibodies Growth media and supplements were purchased from 
Invitrogen (Grand Island, NY).  IGF-I was purchased from GroPep (Adelaide, Australia).  
IGF-II was purchased from Gemini (Woodland, CA). Sulfasalazine (≥98%), L-
Buthionine-sulfoximine (≥97%), N-Acetyl-L-cysteine, LY294002, U0126, and actin 
antibody were purchased from Sigma-Aldrich (St. Louis, MO). Humanized anti-IGF-IR 
monoclonal antibody huEM164 was generously provided by Immunogen Inc. (Norwood, 
MA).  Antibodies for phosphorylated AKT serine 473, total and phospho-IGF-IR, total 
and phospho-phosphorylated p44/42 (MAPK), phospho-p38 MAPK, and IRS-1 were 
purchased from Cell Signaling Technology (Beverly, MA). The IRS-2 antibody was 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).  The xCT antibody for 
Western blot analysis was purchased from Novus Biologicals (Littleton, CO).  
Horseradish peroxidase-conjugated anti-phosphotyrosine (PY-20) was purchased from 
BD Biosciences (San Jose, CA). Anti-rabbit and anti-mouse horseradish peroxidase-
conjugated secondary antibodies were purchased from Pierce (Rockford, IL). 5-(and-6)-
carboxy-2’,7’-dichlorofluorescein diacetate was purchased from Invitrogen (Carlsbad, 
CA). 
 
Cell lines and culture MCF-7, ZR-75-1, T47D, MDA-MB-231, BT549, and HS578T 
cells were purchased from the ATCC (Manassas, VA) and cultured following ATCC’s 
instruction. MCF-7L cells were kindly provided by C. Kent Osborne (Baylor College of 
Medicine) and maintained in improved MEM Richter’s modification medium (zinc 
option) supplemented with 5% FBS and 11.25 nmol/L insulin. MCF-7L were evaluated 
by comparative genomic hybridization and found to be nearly identical to the MCF-7 
cells distributed by the ATCC. MCF-7 TamR cells were generated as described [40]. 
T47D-YA-IRS-1 and T47D-YA-IRS-2 were maintained in Eagle’s Minimal Essential 
Medium supplemented with 5% fetal bovine serum, 11.25 nmol/L insulin, 10 ml/L 100X 
non-essential amino acids, 200 µg/ml of G418, and 200 µg/ml of hygromycin. All cells 
were grown at 37 °C in a humidified atmosphere containing 5% CO2.  
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Immunoblot Cells were plated at a density of 3 x 105 in 60-mm-diameter. Upon reaching 
80% confluency, cells were switched to serum-free medium (SFM) for 24 hour to 
synchronize cell status, after which treatments were added. Treated cells were washed 
twice with ice-cold phosphate buffered saline (PBS) on ice and lysed with lysis buffer of 
50 mM Tris-Cl (pH 7.4), 1% Nonidet P-40, 2 mM EDTA (pH 8.0), 100 mM NaCl, 10 
mM sodium orthovanadate, 1 mM phenylmethysulforny fluoride, and with proteases 
inhibitor cocktails. Lysates were centrifuged at 21,000 rpm for 15 minutes at 4 °C.  
Protein concentrations were measured using the bicinchoninic acid protein assay reagent 
kit (Pierce). Cellular protein (80 µg) was resuspended in 5x Laemmli loading buffer with 
60 mg/ml DTT and was resolved by SDS-PAGE, transferred to nitrocellulose membrane, 
and immunoblotted according to manufacturer guidelines. 
 
siRNA transfection and cell stimulation Cells were cultured in growth medium to reach 
confluency of  80% then were transfected with 30 nmol/L siRNA (siRNAs SMARTpool 
were purchased from Santa Cruz Biotechnology) using the TransIT-siQUEST 
transfection reagent (Mirus, Madison, WI) according to the manufacturer’s protocol. 48 
hours later, cells were washed twice with PBS and serum starved for another 24 hours in 
SFM followed by treatments as indicated in the figure legends. 
 
Stable xCT down-regulation with shRNA 
Lentiviral pKLO.1 vectors encoding a xCT mRNA specific shRNA sequence 
(CCGGGCTGATTTATCTTCGATACAACTCGAGTTGTATCGAAGATAAATCAGC
TTTTTG) or a scrambled shRNA were purchased from BioMedical Genomics Center 
(University of Minnesota) and were introduced to MCF-7 cells.  8 mg/ml polybrene was 
added to increase infection efficiency. MCF-7 cells infected with shRNA were 
maintained by 1 µg/ml puromycin selection pressure.   
 
Reverse transcription-quantitative real-time polymerase chain reaction Cells were 
plated at a density of 2 x 105 in 6-well-plates in growth media to reach 80% confluency 
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then synchronized in SFM for 24 hours followed by treatments indicated in the figure 
legends. Cellular RNA was isolated using TriPure Reagent according to the manufacturer 
(Roche, Belgium). For quality control and to determine concentration, a 260:280 ratio 
assay was conducted on a spectrophotometer. Forward and reverse primers were designed 
to target the following transcripts: SLC7A11 (xCT) 5’-GGCAACCGCGTAATACTTG-3’ 
and 5’-TTGCAAGCTCACAGCAATTC-3’; IRS-1 5’-TCACAGCAGAATGAAGACC-3’ 
and 5’-CTACTGATGAGGAAGATATGAGG-3’; IRS-2 5’-
TCGTGAAAGAGTGAAGATCTG-3’ and 5’-TCCAAACACAGTCATTGCT-3’; 
CD44v 5’-AGAAGGTGTGGGCAGAAGAA-3’ and 5’-
AAATGCACCATTTCCTGAGA-3’; and RPLPO 5’-TGCTGATGGGCAAGAACAC-3’ 
and 5’-GAACACAAAGCCCACATTCC-3’. A total of 1 µg of RNA was reverse 
transcribed using the Transcriptor Reverse Transcriptase Kit, and quantitative PCR was 
conducted using the Universal SYBR Green Kit according to the manufacturer’s protocol 
(Roche) on an Eppendorf (Hamburg, Germany) Mastercycler Realplex4 machine. The 
relative concentration of mRNA was calculated using cycle threshold values that were 
derived from a standard curve and normalized to ribosomal protein, large, PO (RPLPO) as 
an internal control.    
 
Monolayer growth assay Cells were plated in 24-well-plates at a density of 15,000 cells 
per well, allowed to attach overnight and starved in SFM for 24 hours to synchronize 
cells. After 5 days of treatments, growth was assessed via the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 50 µl of 5 mg/ml MTT solution in 
SFM were added to each well and incubated for 4 hours at 37 °C. Media were aspirated 
and formazan crystals were lysed with 500 µl of solubilization solution (95% 
dimethylsulfoxide + 5% improved minimal essential media). Absorbance was measured 
with a plate reader at 570 nm using a 650 nm differential filter to assess growth. 
 
Anchorage-independent growth A 1 ml layer of 1% Seaplaque-agarose (BioWhittaker, 
Rockland, ME) in 1.5% FBS-containing growth media was solidified into each well of a 
6-well plate. The bottom layer was overlaid with 1 ml of a 1% top agar mixture for 
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12,000 cells per well with indicated treatments. All plates were incubated at 37 °C for 14 
days. Colonies was counted on a light microscope with an ocular grid. Five random fields 
were counted per well and only colonies exceeding half of a grid square were scored.  
 
Radiation delivery A dosage from 1~10 Gray was delivered to cell cultures by X-RAD 
320 Biological Irradiator (Precision X-ray, North Branford, CT).  Beam hardening filter= 
2mm Al, dose rate: 3 Gy/min at 320 kV, 12.5 mA, 50 cm SSD.  
 
Glutathione measurement Cells were plated at a density of 10,000 in 96-well clear 
bottom white plates, allowed to equilibrate overnight, and starved in SFM for 24 hours 
followed by treatments. Intracellular reduced glutathione concentrations were measured 
by using GSH/GSSG-Glo™ Assay following manufacturer’s instruction (Promega, 
Madison, WI). Readings were further normalized to CellTiter-Glo® Luminescent Cell 
Viability Assay following the manufacturer’s guideline (Promega). 
 
Glutamic acid assay Cells were plated at a density of 20,000 in 24-well plates, allowed 
to equilibrate overnight, and starved in SFM for 24 hours followed by treatments.  
Glutamic acid level in extracellular media was determined by Amplex® Red Glutamic 
Acid/Glutamate Oxidase Assay Kit according to manufacturer’s protocol (Invitrogen, 
Carlsbad, CA). The glutamic acid readings were further normalized to CellTiter-Glo® 
Luminescent Cell Viability Assay following the manufacturer’s guideline (Promega). 
 
Reactive oxygen species assay Cells were seeded at a density of 10,000 in 96-well clear 
bottom black plates, allowed to equilibrate overnight, and starved in SFM for 24 hours 
followed by treatments. Intracelluar ROS levels were determined by using OxiSelect™ 
Intracellular ROS Assay Kit according to manufacturer’s guideline (Cell Biolabs, Inc., 
San Diego, CA) 
 
Cell cycle analysis Cells were typsinized, washed twice in ice-cold PBS, and fixed in 70% 
ice-cold ethanol -20 °C over night. Cell cycle analyses were performed on propidium 
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iodide-stained nuclei by using a FACSCalibur flow cytometer (Becton-Dickinson 
Biosciences, Heidelberg, Germany). Single cells were gated, 10,000 events were 
collected and analyzed by FlowJo (Tree Star Inc., Ashland, OR) software.   
 
Clinical data set analysis The relative mRNA expression of xCT in human breast tumor 
samples was determined by searching the Oncomine database (version 4.4.3, September 
2012 data release [122]. xCT mRNA expression was queried in TCGA breast dataset 
using reporter A_32_P165472. For prognostic analyses, overall survival and distant 
metastasis-free survival, stratified by expression (all percentiles between the lower and 
upper quartiles were computed, and the best performing threshold was used as a cutoff) 
of the gene of interest (xCT: 207528_s_at), were presented as Kaplan–Meier plots and 
tested for significance using log-rank tests.   
 
Statistical analysis All data except clinical data sets were analyzed with the unpaired 
Student's t test with the use of Excel 2008 (Microsoft, Redmond, WA). A p value of 
<0.05 was considered statistically significant (* p<0.5, ** p<0.01, *** p<0.001). 
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Figure 3.1 IGF-I induced xCT mRNA expression in an IRS-1 dependent manner in breast cancer cell lines.  
A. T47D-YA-IRS-1 and Y47D-YA-IRS-2 cells were grown in SFM for 24 h. After 4 h of IGF-I (5 nM) exposure, 
mRNA was isolated and analyzed by qRT-PCR.  mRNA expression of xCT was normalized to the RPLPO housekeeper 
gene. B. Left: mRNA expression of IRS-1 and IRS-2 in ER positive cell lines: MCF-7, T47D, and ZR-75-1; ER 
negative breast cancer cell lines: MDA-MB-231, BT549, and HS578T were analyzed by qRT-PCR. Right: mRNA 
expression of xCT in SFM or 4 hours after IGF-I exposure was analyzed by qRT-PCR. C. Immunoblot analysis of the 
expression levels of IRS-1 and IRS-2 in indicated breast cancer cell lines. D. mRNA expression of IRS-1 and IRS-2 in 
full growth media were analyzed in MCF-7L and MCF-7L TamR cells (upper panels left). Right: mRNA expression of 
xCT in MCF-7L and MCF-7L TamR cells after 4 h of IGF-I (5 nM), IGF-II (10 nM), or insulin (10 nM) exposure.  
Lower panels right: IRS-1 and IRS-2 protein expression in MCF-7L and MCF-7L TamR cells in full growth media 
condition. xCT expression in MCF-7L and MCF-7L TamR after 24 h of ligand stimulation was analyzed by 
immunoblot (right panel). Data are presented as mean ± standard error of the mean (SEM); all results are representative 
of three independent replicates.   
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Figure 3.2 xCT is overexpressed breast tumor and associated with poor prognosis in ER positive breast cancer. 
A. Oncomine output data was sorted to isolate specified associations as indicated and reported as the mRNA copy 
number unit expression values for normal breast, invasive ductal breast carcinoma, ER positive breast carcinoma, ER 
negative breast carcinoma, and triple negative breast carcinoma samples using box-and-whiskers plots (whiskers: 90/10 
percentiles, box: 75/25 percentiles, line: median of all samples). B. Kaplan-Meier plots of OS (left) and DMFS (right) 
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Figure 3.3 IGF-I induced xCT mRNA and protein expression specifically through IRS-1 and via PI3K 
dependent pathway in MCF-7 cells. 
A. MCF-7 cells were transfected with either 30 nM of control or IRS-1 siRNA for 48h. siRNA knockdown efficiency 
was determined by both qRT-PCR (upper left) and immunoblot analysis (upper right). Cells then were grown in SFM 
for 24 h followed by IGF-I (5 nM) stimulation for 4 h for mRNA measurement (lower left) and 24 h for protein 
detection (lower right). B. MCF-7 cells were grown in SFM for 24 h and pretreated with huEM164 (20 µg/ml) for 24 h; 
pretreated with 10 UO126 (UO; 10 µM), LY294002 (LY; 10 µM), or NVP AEW-541 (AEW; 0.5 µM) for 30 min.  
Cells were then treated with IGF-I for 4 h for qRT-PCR.  Data are mean ± SEM; all qRT-PCR results are representative 
of at least three independent triplicates-experiments.  
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Figure 3.4 IGF-I stimulated xC- transporter function in ER positive breast cancer cells. 
Cells were pretreated with SASP (0.1 mM) for 48 h, BSO (0.05 or 0.1 mM) for 24 h. A. MCF-7, T47D, and MDA-MB-
231 cells were grown in SFM for 24 h then treated with indicated treatments with or without IGF-I (5nM) for another 
24 h. Culture media glutamic acid levels were analyzed and readings were normalized to MTT reading. MCF-7, T47D 
(B), or MDA-MB-231 (C) cells were grown in SFM for 24 h then treated with indicated treatments with or without 
IGF-I (5nM) for another 24 h. Intracellular reduced GSH concentration was determined as described. Data are mean ± 
SEM; all results are representative of three independent replicates. 
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Figure 3.5 IGF-I regulated intracellular ROS level via xC- transporter and through PI3K dependent pathway in 
ER positive breast cancer cells. 
A. MCF-7 and T47D cells were pretreated with or without SASP (0.1 mM) for 48 h, grown in SFM for 24h, treated 
with IGF-I (5 nM) for another 24h, and then irradiated (10 Gy, left panel) or treated with mitomycin C treatment (1 
µg/ml for ROS assay; 0.1 µg/ml for immunoblot) for 3 days (right panel). Intracellular ROS levels were measured as 
described. B. Cellular phospho-p38MAPK level was determined by immunoblot. C. MCF-7 cells were grown in SFM, 
pretreated huEM164 (20 µg/ml), LY294002 (10 µM), or NVP AEW-541 (0.5 µM) (Left panel). MCF-7 cells were 
pretreated with indicated dosage of SASP, BSO, or NAC.  Acute ROS were induced by 5 gy irradiation. MCF-7 cells 
incubated with ROS insensitive probe carboxy-DCFDA (0.1 mM) was presented as assay control (Right panel).  
Cellular ROS levels were determined as described. D. MCF-7 cells were treated with indicated treatments in soft agar.  
After 24h of synchronization in SFM condition, cells were either irradiated or treated with mitomycin C. Colony 
formation was assessed after 14 days.  Survival rate curve was made by normalizing colony number of each treatment 
to its own no treatment control. IC50 values were shown in the table. Data are mean ± SEM; all results are 
representative of three independent replicates. 
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Figure 3.6  Disruption of xC- transporter function resulted in partial suppression in IGF-I-induced cell 
proliferation and sensitized cells to IGF-IR inhibitors. 
A. MCF-7 cells were first pretreated with SASP (0.1 mM) for 48 h or NAC (0.1 mM) for 24 h in SFM and then treated 
with IGF-I (5 nM) for 5 days.  Cell viability was determined by performing MTT assay. B. MCF-7 cells were infected 
by either scrambled shRNA or xCT specific shRNA to generate stable xCT down-regulation clone.  Cells were grown 
in SFM for 24h then treated with IGF-I (5 nM) for 3 days or 5 days.  Cell monolayer growth was measured by MTT 
assay. C. MCF-7 cells were treated with indicated treatment combinations. Anchorage independent growth was 
determined after 14 days. Data are mean ± SEM; all results are representative of three independent replicates. 
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Figure 3.7 siRNA titration in MCF-7 cells. 
MCF-7 cells were treated with indicated concentrations of IRS-1 specific siRNA and Mirus TransIT- siQUEST 
transfection reagent. Cellular IRS-1 protein expression was determined by immunoblot analysis (left). xCT protein 
expression levels upon 24h of IGF-I (5 nM) stimulation in IRS-1 siRNA down- regulated MCF-7 cells were analyzed 
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Figure 3.8 IGF-I induced xCT mRNA and protein expression specifically through IRS-1 in T47D and ZR-75-1 
cells.  
A. T47D and ZR-75-1 cells were transfected with either 30 nM of control or IRS-1 siRNA for 48h. siRNA knockdown 
efficiency was determined by both qRT-PCR (left panels) and immunoblot analysis (right panels). B. T47D and ZR- 
75-1 cells were grown in SFM for 24 h followed by IGF-I (5 nM) stimulation for 4 h for mRNA measurement (left 
panels) and 24 h for protein detection (right panels). Data are mean ± SEM; all results are representative of three 
independent replicates.  
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Figure 3.9 Inhibition of IGF-I signaling. 
MCF-7 cells were grown in SFM, pretreated huEM164 (20 µg/ml), NVP AEW-541 (AEW, 0.5 µM), LY294002 (LY, 
10 µM), or UO126 (UO, 10 µM). Phosphorylated tyrosine (PY20), IGF-1R/IR, AKT, p38MAPK, and MAPK were 
analyzed by immunoblot.  
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Figure 3.10 Effect of SASP, BSO, and NAC concentration on growth. 
A. MCF-7 cells were pretreated with various dosages of SASP for 48 h. Culture media glutamic acid levels were 
analyzed and readings were normalized to titer glo cell viability reading (right). B. MCF-7 cells were pretreated in the 
presence or absence of SASP (0.1 mM). Intracellular GSH concentration was determined as described. C. MCF-7 and 
MDA-MB-231 cells were grown in SFM overnight and treated with various dosages of irradiation. Intracellular ROS 
levels were measured as described. D. MCF-7 or T47D cells were grown in SFM overnight and treated with various 
dosages of mitomycin C (upper panel), BSO (lower left panel), or NAC (lower right panel). Cell viability was 
measured by MTT assay after 3 days of treatment. Data are mean ± SEM; all results are representative of three 
independent replicates. 
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Figure 3.11 IGF-I regulated intracellular ROS level via xC- transporter in MCF-7 and T47D cells but not in 
MDA-MB-231 cells. 
A. MCF-7 and MDA-MB-231 cells were pretreated with or without SASP (0.1 mM) for 48 h, grown in SFM for 24h, 
then treated with IGF-I (5 nM) for another 24h, and then processed for irradiation (10 Gy, left panel) or mitomycin C 
treatment (1 µg/ml) for 3 days (right panel). Intracellular ROS levels were measured as described. B. T47D were 
pretreated with or without SASP (0.1 mM) for 48 h, grown in SFM for 24h, treated with IGF-I for another 24h, and 
then treated with mitomycin C (0.1 µg/ml) cellular phospho-p38MAPK level was determined by immunoblot. Data are 
mean ± SEM; all results are representative of three independent replicates. 
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Figure 3.12 xCT shRNA downregulation in MCF-7 cells. 
MCF-7 cells were infected by either scrambled shRNA or xCT specific shRNA to generate stable xCT downregulation 
clone. shRNA downregulation efficiency was determined by qRT-PCR (upper left panel), immunoblot (upper right 
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Figure 3.13 Ligands of the insulin/IGF system stimulated xCT mRNA expression but not CD44v mRNA 
expression in MCF-7 cells. 
mRNA expression of xCT (left) and CD44v (right) in MCF-7 cells after 4 h of IGF-I (5 nM), IGF-II (10 nM), or insulin 
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Figure 3.14 BSO mediated cellular behaviors assays in MCF-7 cells. 
A. MCF-7 cells were treated with indicated treatments in soft agar. After 24h of synchronization in SFM condition, 
cells were either irradiated or treated with mitomycin C. Colony formation was assessed after 14 days. Survival rate 
curve was determined by normalizing colony number of each treatment to its own no treatment control. Statistically 
significant differences are noted (* or # p<0.5, ** or ## p<0.01, *** or ### p<0.001). The table shows IC50 values. B. 
MCF-7 cells were first pretreated with BSO (0.05 mM) or NAC (0.1 mM) for 24 h, grown in SFM for 24h and then 
treated with IGF-I (5 nM) for 5 days. Cell viability was determined by performing MTT assay. C. MCF-7 cells were 
treated with indicated treatment combinations. Anchorage independent growth was determined after 14 days. Data are 
mean ± SEM; all results are representative of three independent replicates. 
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Figure 3.15 Inhibition of xCT suppressed basal proliferation and migration in MDA-MB-231 cells. 
MDA-MB-231 cells were treated with SASP (0.1 mM) or transfected with shRNAs specific targeting xCT. Cells 
proliferation and migration were measured by MTT monolayer growth assay (A) and boyndern chamber migration 
assay (B) respectively. C. Basal expression of xCT in T47D-YA and T47D-YA-IRS-1 cells were assessed by western 
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Introduction 
Nuclear factor-erythroid 2-related factor 2 (Nrf2) is a master transcriptional 
activator that specifically binds to the antioxidant response element (ARE) to initiate 
expression of various anti-oxidative and anti-inflammatory genes to protect cells from 
oxidative stress. One of Nrf2’s canonical transcriptional targets is xCT. Normally, 
cytosolic Nrf2 is constantly bound to Keap1 to be ubiquitinated and degraded by 
proteasome. Inactivation of Keap1 stabilizes Nrf2 and promotes its translocation into the 
nucleus where Nrf2 binds to ARE and initiates the transcription of cytoprotective genes. 
Constitutive stabilization of Nrf2 has been observed in many human cancers and confers 
chemo- and radio-resistance of cancer cells. Recently, Nrf2 has been shown to redirect 
glucose and glutamine into anabolic pathways to reduce cellular redox level and promote 
cell proliferation in lung carcinoma models [152].  
 
Breast cancer is the second most diagnosed malignancy and second leading cause 
of cancer death among women in the United States (American Cancer Society). 
Molecular profiling has identified at least four subtypes of breast cancer: luminal A, 
luminal B, triple negative/basal-like, and human epidermal growth factor receptor 2 
(Her2)-enriched breast cancer. Successes in developing hormonal therapy (estrogen 
receptor antagonists and aromatase inhibitors) [1, 153] and Her2-targeted therapy [154] 
have significantly decreased breast cancer mortality in the past few decades. However, 
the conquest of breast cancer still faces great challenge due to the extreme heterogeneous 
nature of this disease. 
 
Estrogen receptor positive (ER+) breast cancer patients are treated with endocrine-
targeted therapy, de novo or acquired resistances often happen years after the initial 
treatment, which makes ER+ breast cancer still an incurable disease and novel molecular 
targets or novel combination therapies are in need to be established. 
 
The insulin-like growth factor (IGF) signaling system has been well documented to 
regulate ER+ breast cancer proliferation [6, 105]. However, type 1 IGF receptor (IGF-
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IR)-targeted therapy concurs obstacles in processing to late phase clinical trials possibly 
due to lack of predictive biomarkers or inappropriate combination therapies [105, 119]. 
Previous studies indicated that estrogen regulates Nrf2 expression and function in 
hormone sensitive, insensitive, and BRCA mutant breast cancer cells via 
Phosphoinositide 3-kinase (PI3K) signaling pathway [155, 156]. Crosstalk between 
estrogen receptor and IGF signaling system has been extensively studied [157]. Crosstalk 
between IGF signaling system and Nrf2 has not yet been explored. Since estrogen and 
IGF signaling system both activate PI3K-AKT pathway and in the previous chapter we 
reported that IGF-I regulates Nrf2’s canonical transcriptional target xCT, we proposed 
that IGF/insulin signaling pathway may regulate Nrf2 expression and function in ER+ 
breast cancer cells.  
 
About 20% of breast cancer patients are diagnosed as triple negative/basal-like 
(estrogen receptor, progesterone receptor, and Her2 negative) breast cancer (TNBC). The 
lack of these molecular targets causes TNBC/basal-like cells unresponsive to hormonal 
therapy or Her2-targeted therapy, which makes it the most aggressive subtype and with 
poorest prognosis. To date, there is no established targeted therapy for TNBC/basal-like 
patients thus identifying novel therapeutic targets is eagerly needed. A recent study 
showed that TNBC/basal-like cell lines were extremely sensitive to glutamine restriction 
which decreased cystine import via xC- transporter, which was critically required for 
synthesis of the reduced form of glutathione (GSH) [114, 128] and was upregulated in 
TNBC/basal-like cells [114, 158]. Inhibition of xC- resulted in reduced GSH, increased 
reactive oxygen species (ROS), and inhibited growth of the TNBC cells [158]. 
TNBC/basal-like breast cancer cells are well known for their stem-like (CD44+/CD24-) 
properties. Cancer stem cells contain lower level of ROS and are often radioresistance 
[159]. xC- has been reported to be directly regulated by Nrf2 [128, 160]. Taken together, 
we hypothesized that Nrf2 expression may also be highly expressed in TNBC/basal-like 
breast cancer cell lines and may contribute to clonogenicity, stemness maintenance, and 
radioresistance.  
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The aim of this study was to thoroughly investigate the IGF’s regulation on Nrf2 in 
ER+ breast cancers and evaluate Nrf2 as a target in TNBC/basal-like breast cancers. 
 
Results 
Nrf2 expression and its prognostic value in breast cancer cell lines and patients 
To address whether Nrf2 expression was upregulated in certain subtypes of breast 
cancer cells, mRNA levels of Nrf2 (NFE2L2) were quantified in a panel of breast cancer 
cell lines (Figure 4.1 A, B left panel). Protein expression of Nrf2 was further confirmed 
in selected cell lines by immunoblot (Figure 4.1 B right panel). Nrf2 expression was 
generally significantly higher in TNBC/basal-like breast cancer cells than immortalized 
or ER+ cell lines. Prognostic value of Nrf2 expression was also assessed by using an 
online survival analysis tool [123]. The result suggested that higher expression of Nrf2 
was associated with poor prognosis in all breast cancer patients (TCGA database) (Figure 
4.1 C). 
 
IGF-I regulated Nrf2 protein expression and function in ER+ breast cancer cells 
Nrf2 basal expression was relatively low in ER+ breast cancer cells. Nrf2 is 
detected as two bands corresponding to its phosphorylation status.  IGF signaling system 
ligands (IGF-I, IGF-II, and insulin) stimulated Nrf2 protein expression while suppressing 
the expression of intracellular redox indicator phospho-p38MAPK in MCF-7 and T47D 
cells (Figure 4.2 A). The insulin receptor substrates (IRS) are important regulators of 
IGF-IR and insulin receptor signaling [105, 119]. Control, IRS-1, or IRS-2 siRNAs was 
introduced to MCF-7 and T47D cells to examine the effect on Nrf2 induction. Only IRS-
1 downregulation attenuated IGF-I-induced Nrf2 expression, which implied that the 
regulation was through IRS-1 protein (Figure 4.2 B top panels). Cells were further treated 
with anti-IGF-IR monoclonal antibody huEM164, IGF-IR/ insulin receptor kinase 
inhibitor BMS-754807, or PI3K inhibitor LY294002 prior to IGF-I stimulation. All three 
inhibitors suppressed IGF-I regulation of Nrf2 implicating the role for activation of IGF-
IR and PI3K in Nrf2 expression (Figure 4.2 B bottom panel). IGF-I promoted the nuclear 
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translocation of phospho-Nrf2, which was eliminated by pretreating cells with IGF-
IR/insulin receptor kinase inhibitor NVP-AEW541 (Figure 4.2 C).  
 
Nrf2 suppression resulted in intracellular redox upregulation in MCF-7 cells 
To assess Nrf2 as a target in ER+ breast cancer cells, siRNA or short hairpin RNAs 
to Nrf2 were introduced to MCF-7 and T47D cells (Figure 4.3 A, C right, D, 4.8 A). Nrf2 
downregulation resulted in significantly suppression of its typical target genes: GCLC, 
GCLM, xCT, and NQO-1; as well as genes coding for the enzymes in the pentose 
phosphate pathway (PPP): G6PD, PGD, ME-1, PPAT, TALDO1, TKT, and MTHFD2 
(Figure 4.3 B, 4.8 B). The Nrf2 downregulation did not affect the expression of unrelated 
genes: CD44 (Figure 4.3 B, 4.8 B). Nrf2 knockdown also resulted in increased 
intracellular reactive oxygen species (ROS) in MCF-7 cells (Figure 4.3 C). Suppression 
of Nrf2 led to lower levels of cytoprotective gene expression and should result in reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) production in the PPP, which 
may have contributed to the elevation of intracellular ROS. While Nrf2 downregulation 
did not significantly suppress IGF-I-stimulated cell proliferation (Figure 4.3 D), however 
suppression of Nrf2 abrogated the IGF-I mediated protection from irradiation (Figure 4.3 
E right panel). 
 
Nrf2 suppression resulted in redox upregulation in MDA-MB-231 and MDA-MB-
436 cells 
MDA-MB-231 and MDA-MB-436 cells expressed high basal levels of Nrf2 
(Figure 4.1A, B) and IGF-I did not further increase Nrf2 expression (Figure 4.9). 
Downregulation of Nrf2 (Figure 4.4 A, 4.9) resulted in activation of AMPKα, and 
p38MAPK (Figure 4.9, 4.10 A; 4.4 C left); suppression of PPP enzymes coding genes: 
G6PD, PGD, ME-1, TALDO1, and TKT; and suppression of typical Nrf2 regulated genes: 
GCLC, GCLM, xCT, and NQO-1 (Figure 4.4 B, 4.11 A, B). Citric acid cycle metabolism 
analysis was further performed in control and Nrf2 downregulated MDA-MB-231 cells. 
Nrf2 down-regulated cells showed reduced NADPH production, reduced ATP production, 
decreased intermediates involved in PPP pathway, and increased intermediates in 
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glycolysis pathway, which were consistent with the gene expression change: cells were 
redirected to glycolytic pathway instead of PPP (Table 4.1). Direct measurement of 
intracellular ROS showed redox increase in Nrf2 downregulation clones (Figure 4.4 D, 
4.11 C). In TNBC/basal-like cells, cysteine/glutamate antiporter xC- (coded by SLC7A11) 
has been identified as a potential drug target [158]. Nrf2 directly regulated xCT 
expression (Figure 4.4 A, B right panel, 4.9, 4.11 A, B). xC- together with GCLC and 
GCLM are necessary for intracellular cysteine transport and subsequent production of 
glutathione (GSH). Nrf2 downregulation caused depletion of GSH and increased cellular 
ROS, which were partially restored when overexpressing xCT in the Nrf2 knockdown 
clone (Figure 4.4 C, D, E).  
 
It is known that mitochondrial membrane potential controls ATP synthesis. 
Activation of AMPKα in Nrf2 downregulated cells (Figure 4.4 C right, 4.9, 4.10 A) 
suggested an increased intracellular ADP/ATP ratio (Table 4.1) thus also implied 
mitochondrial function impairment. To confirm this, mitochondrial membrane potential 
assay detecting active mitochondria in living cells were performed in controlled and Nrf2 
downregulated MDA-MB-231 cells. The results indicated that loss of Nrf2 impaired 
mitochondrial function (Figure 4.4 F). Overexpressing xCT did not rescue impaired 
mitochondrial function in Nrf2 downregulated cells as indicated by AMPKα status 
(Figure 4.4 C right) indicating xCT was not implicated in the regulation of the 
glycolysis/PPP metabolic pathway. ARE-GFP reporter assays showed that ARE binding 
activity was not detectable when Nrf2 was suppressed (Figure 4.4 G). Collectively, these 
data suggested that in TNBC/basal-like cells, Nrf2 regulated ROS and cellular GSH level 
partially through xC- transporter function and partially through the regulation of PPP.  
 
Nrf2 suppression resulted in growth inhibition in TNBC/basal-like cells 
Loss of Nrf2 decreased mitochondrial potential as well as elevated cellular redox 
level. To assess the biological consequences of this regulation, monolayer growth assay, 
clonogenic assay, and three-dimensional culture in Matrigel were performed. All these 
assays showed significant growth inhibition in Nrf2 downregulated clones (Figure 4.5 A, 
  85 
B, C, 4.11 D). Cell cycle analysis further demonstrated that loss of Nrf2 caused G0/G1 
increase and S phase decrease (Figure 4.5 D).Overexpressing xCT in Nrf2 downregulated 
cells partially rescued the growth inhibitory phenotype (Figure 4.5 A right, B) All trans 
retinoic acid (ATRA) has been reported as an inhibitor function as competitively inhibits 
the binding of Nrf2 to the ARE enhancer [161]. In this study, ATRA reduced 
mitochondrial potential (Figure 4.4 F), while signaling analysis also showed that retinoic 
acid induced the activation of AMPKα (Figure 4.10 A). ATRA inhibited MDA-MB-231 
cell proliferation in a dose dependent manner (Figure 4.10 B). Taken together, the data 
indicated that target Nrf2 by genetic knockdown or chemical inhibitor both resulted in 
growth inhibition in TNBC/basal-like cells. 
 
Nrf2 suppression sensitized MDA-MB-231 response to irradiation 
Nrf2 expression contributes to chemo- and radiation therapy resistance. Targeting 
Nrf2 by shRNA knockdown significantly sensitized MDA-MB-231 response to 
irradiation in both monolayer and anchorage independent growth conditions (Figure 4.6 
A, B, C). MDA-MB-231 has stem cell-like properties as characterized by cell surface 
markers (CD44+/CD24-). Cancer stem cells are considered to be resistant to multiple 
cancer therapies due to their slow self-renewal rate. xCT has been reported to stabilize 
cell surface CD44 expression in a colorectal cancer model [133]. As mentioned above, 
Nrf2 directly suppressed xCT mRNA and protein expression (Figure 4.4 A, B right panel, 
4.11 A, B right panel). Cell surface CD makers were analyzed in MDA-MB-231 control 
and Nrf2 downregulated cells under normal and stressed conditions induced by hydrogen 
peroxide. Data suggested that loss of Nrf2 decreased the CD44+/CD24- stem cell 
population (Figure 4.5 D top panels). This decrease was further enlarged when cells were 
under stressed condition induced by hydrogen peroxide (Figure 4.5 D bottom panels). 
Overexpression of xCT in Nrf2 downregulated clone rescued CD44+/CD24- population 
(Figure 4.12).  
 
Nrf2 suppression reduced migration potential in MDA-MB-231 cells 
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Besides growth arrest, Nrf2 downregulated cells also showed morphologic changes 
(Figure 4.7 A). IGF-I stimulated migration was abolished in Nrf2 downregulated MDA-
MB-231 cells (Figure 4.7 B). To understand the mechanism, mesenchymal markers were 
further analyzed. Data suggested that the reduced migration potential might due to 
regulation of vimentin and snail (Figure 4.7 C, D). 
 
Discussion 
In the first half of this study, we have shown that IGF signaling regulated Nrf2 
expression in a PI3K dependent pathway that involves IRS-1 adaptor protein in ER+ 
breast cancers. In our previous study, we found that IGF system also regulates xC- 
transporter expression and function to promote cancer cell proliferation through IRS-1-
PI3K regulated signaling pathway[114]. Given that xC- is a direct transcriptional target of 
Nrf2, the data are consistent suggesting a therapy targeting both Nrf2/xC- and IGF-IR in 
conjunction with conventional chemotherapy or radiotherapy may have synergistic 
effects in ER+ breast cancers.  
 
ER+ breast cancers frequently acquire resistance to endocrine therapies. In the 
supplementary data, we found that tamoxifen resistant breast cancer cells expressed lower 
levels of Nrf2 than the parental counterparts (Figure 4.13 A, B). Further analysis also 
showed that the canonical targets of Nrf2 were downregulated (Figure 4.13 A), while 
intracellular ROS levels were increased as indicated by the activation of p38MAPK (Figure 
4.13 B) in tamoxifen resistant breast cancer cells. Moreover, data also suggested that 
tamoxifen resistant cells were more sensitive to irradiation possibly due to the loss of 
Nrf2 (Figure 4.13 C).  
 
The growth of TNBC/basal-like breast cancer cells was dependent on Nrf2 
expression and IGF signaling did not affect Nrf2 expression or function. We confirmed 
the six genes involved in the PPP and NADPH production pathways in addition to GCLC, 
GCLM, xCT, and NQO-1 were direct targets of Nrf2 in TNBC/basal-like cell lines. Nrf2 
scavenged intracellular ROS in TNBC/basal-like breast cancer cells via two pathways: 
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PPP metabolic pathway and traditional cytoprotective pathway. By targeting Nrf2, cell 
metabolism switched to glycolysis, less NADPH was produced, and ROS increased, 
which resulted in impairment of mitochondrial function as indicated by hyper-activation 
of AMPKα and direct measurement of mitochondrial membrane potentials. Meanwhile, 
Nrf2 suppression also led to the decrease of cellular GSH synthesis due to the 
downregulation of cysteine importer xC- and glutamate-cysteine ligase GCLC and GCLM. 
Moreover, the loss of xCT caused cell surface CD44+/CD24- stem cell population 
elimination [133]. Nrf2 downregulation did not affect CD44 expression. Overexpression 
of xCT in Nrf2 downregulated cells restored CD44+/CD24- population, intracellular 
reduced GSH level, and partially rescued cellular ROS level. As previous studies 
suggested, CD44+ cancer stem cells manifest upregulation of antioxidant genes and 
possess an enhanced ROS defense system therefore are relatively radioresistant [159, 
162]. All the above contributed to sensitization of MDA-MB-231 cells to irradiation.  
 
In addition to the citric acid cycle metabolism analysis, we also performed amino 
acid metabolomics profiling in the scramble and Nrf2 shRNA infected MDA-MB-231 
cells. Among 23 amino acids, the levels of hydroxyproline, histidine, and cystine were 
not detectable due to sample preparation or sensitivity limitation of the mass 
spectrometry. Alanine was downregulated while glycine and aspartic acid were 
significantly increased in the Nrf2 knockdown cells (Figure 4.14). In a recent report 
which compared metabolomics differences between ER+ and ER- breast cancer, alanine 
demonstrated the strongest differences between ER- and ER+ breast tumors [163]. These 
findings suggested that alanine metabolism might affect cancer cell phenotype. 
Additional research should be conducted to explore Nrf2’s regulation on cellular amino 
acid metabolomics and its potential contribution to cancer malignancy and phenotypes.  
 
Materials and Methods 
 
Reagents and antibodies Growth media and supplements were purchased from 
Invitrogen (Grand Island, NY). IGF-I was purchased from GroPep (Adelaide, Australia). 
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IGF-II was purchased from Gemini (Woodland, CA). Sulfasalazine (≥98%), L-
Buthionine-sulfoximine (≥97%), N-Acetyl-L-cysteine, LY294002, U0126, and actin 
antibody were purchased from Sigma-Aldrich (St. Louis, MO). Humanized anti-IGF-IR 
monoclonal antibody huEM164 was generously provided by Immunogen Inc. (Norwood, 
MA). BMS-754807 was provided by Bristol Myers Squibb (New Jersey, Marco 
Gottardis). Antibodies for phosphorylated AMPKα, phospho-p38MAPK, xCT, and 
phsopho-PERK were purchased from Cell Signaling Technology (Beverly, MA). The 
keap1 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The 
total and phospho-Nrf2 antibody for Western blot analysis was purchased from Abcam 
(Cambridge, MA). Anti-rabbit and anti-mouse horseradish peroxidase-conjugated 
secondary antibodies were purchased from Pierce (Rockford, IL). 5-(and-6)-carboxy-
2’,7’-dichlorofluorescein diacetate was purchased from Invitrogen (Carlsbad, CA). 
 
Cell lines and culture Breast cancer cell lines were purchased from the ATCC 
(Manassas, VA) and cultured following ATCC’s instruction. MCF-7L cells were kindly 
provided by C. Kent Osborne (Baylor College of Medicine) and maintained in improved 
MEM Richter’s modification medium (zinc option) supplemented with 5% FBS and 
11.25 nmol/L insulin. MCF-7L were evaluated by comparative genomic hybridization 
(data not shown) and found to be nearly identical to the MCF-7 cells distributed by the 
ATCC. MCF-7 TamR cells were generated as described [40]. All cells were grown at 
37 °C in a humidified atmosphere containing 5% CO2.  
 
Immunoblot Cells were plated at a density of 3 x 105 in 60-mm-diameter. Upon reaching 
80% confluency, cells were switched to serum-free medium (SFM) for 24 hour to 
synchronize cell status, after which treatments were added. Treated cells were washed 
twice with ice-cold phosphate buffered saline (PBS) on ice and lysed with lysis buffer of 
50 mM Tris-Cl (pH 7.4), 1% Nonidet P-40, 2 mM EDTA (pH 8.0), 100 mM NaCl, 10 
mM sodium orthovanadate, 1 mM phenylmethysulforny fluoride, and with proteases 
inhibitor cocktails. Lysates were centrifuged at 21,000 rpm for 30 minutes at 4 °C. 
Protein concentrations were measured using the bicinchoninic acid protein assay reagent 
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kit (Pierce). Cellular protein (80 µg) was resuspended in 5x Laemmli loading buffer with 
60 mg/ml DTT and was resolved by SDS-PAGE, transferred to nitrocellulose membrane, 
and immunoblotted according to manufacturer guidelines. 
 
siRNA transfection and cell stimulation Cells were cultured in growth medium to reach 
confluency of 80% then were transfected with 30 nmol/L siRNA (siRNAs SMARTpool 
were purchased from Santa Cruz Biotechnology) using the TransIT-siQUEST 
transfection reagent (Mirus, Madison, WI) according to the manufacturer’s protocol. 48 
hours later, cells were processed to indicate experimental procedure. 
 
Stable Nrf2 down-regulation with shRNA 





AAACCCAGGGCTGCCTTGGAAAAG-3') or a scrambled shRNA were purchased 
from BioMedical Genomics Center (University of Minnesota) and were introduced to 
MCF-7, T47D, MDA-MB-231, and MDA-MB-436 cells. 8 mg/ml polybrene was added 
to increase infection efficiency. MCF-7 and T47D cells infected with shRNA were 
maintained by 1 µg/ml puromycin selection pressure, while MDA-MB-231 cells and 
MDA-MB-436 cells were maintained by 1.5 µg/ml and 2 µg/ml puromycin selection 
pressure respectively.  
 
Overexpression of xCT 
Lentiviral pLOC vector encoding the open reading frame of SLC7A11 without stop 
codon (OHS5898-219582558) was purchased from Dharmacon (Lafayette, CO) and was 
introduced to MDA-MB-231 and MDA-MB-436 cells. 8 mg/ml polybrene was added to 
increase infection efficiency. Infected cells were maintained by 5 – 15 µg/ml blasticidin 
select pressure. 
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Reverse transcription-quantitative real-time polymerase chain reaction Cells were 
plated at a density of 2 x 105 in 6-well-plates in growth media to reach 80% confluency 
then synchronized in SFM for 24 hours followed by treatments indicated in the figure 
legends.  Cellular RNA was isolated using TriPure Reagent according to the 
manufacturer (Roche, Belgium).   For quality control and to determine concentration, a 
260:280 ratio assay was conducted on a spectrophotometer.  Forward and reverse primers 
were designed to target the following transcripts: SLC7A11 (xCT) 5’-
GGCAACCGCGTAATACTTG-3’ and 5’-TTGCAAGCTCACAGCAATTC-3’; NFE2L2 
(Nrf2) 5’-CAAGACTTGGGCCACTTAAAAGAC-3’ and 5’-
AGTAAGGCTTTCCATCCTCATCAC-3’; G6PD 5’-
TGACCTGGCCAAGAAGAAGA-3’ and 5’-CAAAGAAGTCCTCCAGCTTG-3’; PGD 
5’- ATATAGGGACACCACAAGACGG-3’ and 5’-GCATGAGCGATGGGCCATA-3’; 
ME-1 5’-GGAGCTCCAGGTCCTTAGAA-3’ and 5’-TGAGCACGCTGTAGAAGAGC-
3’; PPAT 5’-AATAGCTGTGGCCCATAACG-3’ and 5’-
ACGTGGAAAGCCCAATACC-3’; TALDO1 5’-GTCATCAACCTGGGAAGGAA-3’ 
and 5’-CAACAAATGGGGAGATGAGG-3’; TKT 5’-
GCTGAACCTGAGGAAGATCA-3’ and 5’-TGTCGAAGTATTTGCCGGTG-3’; 
MTHFD2 5’-CCGCCAGTCACTCCTATGTT-3’ and 5’-
TCCTCTGAAACTGAGGCTGG-3’; NQO-1 5’-AGCTGGAAGCTGCAGACCTG-3’ 
and 5’-CCTTTCAGAATGGCTGGCA-3’; SLC3A2 5’-
ACCGGGGTGAGAACTCGTGGT-3’ and 5’-TGGAACCCATCCACGCCAGC-3’; 
SLC7A5 5’-GGCAACCGCGTAATACTTG-3’ and 5’-TTGCAAGCTCACAGCAATTC-
3’; GCLC 5’-TGCGAAAACGCCGGAAGGAGG-3’ and 5’-
ACCTCGGGCAGTGTGAACCCA-3’; GCLM 5’-AAGTGCCCGTCCACGCACAG-3’ 
and 5’-ACTCCCTGACCAAATCTGGGTTGA-3’; CD44 5’-
AGAAGGTGTGGGCAGAAGAA-3’ and 5’-AAATGCACCATTTCCTGAGA-3’; 
CD44v 5’-AGAAGGTGTGGGCAGAAGAA-3’ and 5’-
AAATGCACCATTTCCTGAGA-3’; SNAIL 5’-ACCACTATGCCGCGCTCTT-3’ and 
5’-GGTCGTAGGGCTGCTGGAA-3’; SLUG 5’-TGTTGCAGTGAGGGCAAGAA-3’ 
and 5’-GACCCTGGTTGCTTCAAGGA-3’; TWIST1 5’-
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CGACGACAGCCTGAGCAACA-3’ and 5’-TGCAGCTCCTCGTACGACTG-3’; ZEB1 
5’-GCACCTGAAGAGGACCAGAG-3’ and 5’-TGCATCTGGTGTTCCATTTT-3’; 
CDH1 5’-ACGTTAGCCTCGTTCTCAGG-3’ and 5’-
TGAGGGGTTAAGCACAACAG-3’; and RPLPO 5’-TGCTGATGGGCAAGAACAC-3’ 
and 5’-GAACACAAAGCCCACATTCC-3’.  A total of 1 µg of RNA was reverse 
transcribed using the Transcriptor Reverse Transcriptase Kit, and quantitative PCR was 
conducted using the Universal SYBR Green Kit according to the manufacturer’s protocol 
(Roche) on an Eppendorf (Hamburg, Germany) Mastercycler Realplex4 machine.  The 
relative concentration of mRNA was calculated using cycle threshold values that were 
derived from a standard curve and normalized to ribosomal protein, large, PO (RPLPO) as 
an internal control.    
 
Monolayer growth assay Cells were plated in 24-well-plates at a density of 15,000 cells 
per well, allowed to attach overnight and starved in SFM for 24 hours to synchronize 
cells.  After 5 days of treatments, growth was assessed via the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) assay.  50 µl of 5 mg/ml MTT solution in 
SFM were added to each well and incubated for 4 hours at 37 °C.  Media were aspirated 
and formazan crystals were lysed with 500 µl of solubilization solution (95% 
dimethylsulfoxide + 5% improved minimal essential media).  Absorbance was measured 
with a plate reader at 570 nm using a 650 nm differential filter to assess growth. 
 
Anchorage-independent growth A 1 ml layer of 1% Seaplaque-agarose (BioWhittaker, 
Rockland, ME) in 1.5% FBS-containing growth media was solidified into each well of a 
6-well plate.  The bottom layer was overlaid with 1 ml of a 1% top agar mixture for 
12,000 cells per well with indicated treatments. All plates were incubated at 37 °C for 14 
days. Colonies was counted on a light microscope with an ocular grid. Five random fields 
were counted per well and only colonies exceeding half of a grid square were scored.  
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Radiation delivery A dosage from 1~10 Gray was delivered to cell cultures by X-RAD 
320 Biological Irradiator (Precision X-ray, North Branford, CT).  Beam hardening filter= 
2mm Al, dose rate: 3 Gy/min at 320 kV, 12.5 mA, 50 cm SSD.  
 
Glutathione measurement Cells were plated at a density of 10,000 in 96-well clear 
bottom white plates and allowed to equilibrate overnight followed by treatments. 
Intracellular reduced glutathione concentrations were measured by using GSH/GSSG-
Glo™ Assay following manufacturer’s instruction (Promega, Madison, WI). Readings 
were further normalized to CellTiter-Glo® Luminescent Cell Viability Assay following 
the manufacturer’s guideline (Promega). 
 
Reactive oxygen species assay Cells were seeded at a density of 10,000 in 96-well clear 
bottom black plates, allowed to equilibrate overnight, and starved in SFM for 24 hours 
followed by treatments. Intracelluar ROS levels were determined by using OxiSelect™ 
Intracellular ROS Assay Kit according to manufacturer’s guideline (Cell Biolabs, Inc., 
San Diego, CA) 
 
Mitochondrial potential measurement Cells were seeded and treated with indicated 
reagents then mitochondrial potential were measured by following the instruction of 
TMRE-Mitochondrial membrane potential assay kit (Abcam, Cambridge, MA). 
 
Radiation delivery A dosage from 1~10 Gray was delivered to cell cultures by X-RAD 
320 Biological Irradiator (Precision X-ray, North Branford, CT).  Beam hardening filter= 
2mm Al, dose rate: 3 Gy/min at 320 kV, 12.5 mA, 50 cm SSD.  
 
Metabolic profiling Cells were seeded, equilibrated, and quenched following the 
instruction provided by University of Michigan Metabolomics Core. 
 
Cell cycle analysis Cells were typsinized, washed twice in ice-cold PBS, and fixed in 70% 
ice-cold ethanol -20 °C over night. Cell cycle analyses were performed on propidium 
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iodide-stained nuclei by using an AccuriTM C6 flow cytometer (BD Biosciences, San Jose, 
CA). Single cells were gated, 10,000 events were collected and analyzed by FlowJo (Tree 
Star Inc., Ashland, OR) software.  
 
Three-dimensional cell culture 0.8 x 105 MDA-MB-231 cells were seeded in 12-well 
plates on top of matrigel. Detailed protocol was extensively described previously [164]. 
 
Boyden chamber migration assay Cell motility and invasion were measured by a 
modified Boyden chamber assay as described previously[5]. Cells were briefly detached 
by trypsin, washed twice with SFM, and then resuspended in SFM with or without 
NT157 compound. Cells (150,000) were placed in the upper chamber of a 10-well 
Boyden chamber apparatus. Upper and lower chambers were separated by a 
polycarbonate polyvinylpyrrolidone–free filter with 8-µm pores. SFM (0.4 mL) with or 
without IGF (5 nmol/L) was placed in the bottom wells of the chamber. After 5 h of 
incubation at 37°C in a humidified atmosphere containing 5% CO2, cells remaining on 
the topside of the filter were removed with cotton swabs. The filter was then removed 
from the chamber and the cells that had migrated to the underside of the filter were fixed 
and stained in HEMA3. The filter was then mounted onto a glass microscope slide and 
cells were counted (in triplicate) in five different areas using a light microscope. 
 
Clinical data set analysis The relative mRNA expression of xCT in human breast tumor 
samples was determined by searching the Oncomine database (version 4.4.3, September 
2012 data release [122]. xCT mRNA expression was queried in TCGA breast dataset 
using reporter A_32_P165472.  For prognostic analyses, overall survival and distant 
metastasis-free survival, stratified by expression (all percentiles between the lower and 
upper quartiles were computed, and the best performing threshold was used as a cutoff) 
of the gene of interest (NFE2L2, 201146_at), were presented as Kaplan–Meier plots and 
tested for significance using log-rank tests.   
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Statistical analysis All data except clinical data sets were analyzed with the unpaired 
Student's t test with the use of Excel 2008 (Microsoft, Redmond, WA). A p value of 
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Figure 4.1 Upregulation of Nrf2 expression in TNBC/basal-like breast cancer cell lines and had prognostic value 
in patients’ samples. 
A. Total RNA was isolated from a panel of immortalized breast epithelial cell lines and breast cancer cell lines, and 
reverse transcribed to DNA. NFE2L2 gene expression was quantified by qRT-PCR. L indicates Luminal; B indicates 
Basal-like. B. mRNA (left) and protein (right) expressions of Nrf2 in indicated breast cancer cell lines. C. Kaplan-
Meier plots of refractory free survival (RFS) of patients with breast cancer. Data was obtained from the Kaplan-Meier 
plotter database [16]. qRT-PCR data were normalized to RPLP0 housekeeper gene. Graphic data are mean ± SEM; 
results are representative of at least three independent triplicates experiments. 
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Figure 4.2 IGF signaling system regulated Nrf2 protein expression and function in ER+ breast cancer cells. 
A. MCF-7 (left) and T47D (right) cells were serum starved overnight then treated with or without IGF-I (5 nM), IGF-II 
(10 nM), or insulin (10 nM) for 24 hours. Cellular lysates were separated by SDS-PAGE and indicated protein levels 
were assessed by immunoblotting. B. Top panels: MCF-7 (left) or T47D (right) cells were transfected with control, 
IRS-1, or IRS-2 siRNAs (25 nM) for 48 hours. Cells were serum starved then treated with or without IGF-I (5 nM) for 
24 hours. Indicated protein levels were analyzed by immunoblotting. Bottom panel: MCF-7 cells were serum starved 
overnight then pretreated with huEM164 (164, 20 µg/ml, 24 hr), BMS-754807 (BMS, 1 nM, 1hr), or LY294002 (LY, 
10 µM, 1hr). Protein levels of total Nrf2, phospho-p38MAPK, and actin were determined by immunoblotting. The 
intensity of Nrf2 bands were further digitized and quantified by ImageJ then normalized to the reading (as the 
denominator) of the first lane of each experiment. The numbers indicated the relative intensities of total Nrf2 bands. C. 
MCF-7 cells were pretreated with or without AEW-541 (AEW, 1 nM, 1 hr) and serum starved overnight then treated 
with or without IGF-I (5 nM) for indicated time period. Cytoplasmic and nucleus phosphor-serine 40 Nrf2 protein were 
extracted and assessed by immunoblotting. 
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Figure 4.3 Nrf2 suppression resulted in intracellular redox upregulation in MCF-7 cells. 
A. MCF-7 cells were transfected with control or Nrf2-targeted siRNAs (25 nM) for 48 hours. Protein expressions were 
assessed by immunoblotting. B. MCF-7 cells were transfected with control or Nrf2 siRNAs (25 nM) for 48 hours. 
mRNA expressions of PPP metabolic pathway related genes (left) and ROS pathway related genes (right) were 
quantified by qRT-PCR. C. Cellular ROS levels of indicated manipulated MCF-7 cells were measured and normalized 
to cell viability titer glo readings (left). Nrf2 shRNA downregulation efficiency was analyzed by qRT-PCR (right). D. 
Indicated shRNAs infected MCF-7 cells were serum starved overnight then treated with IGF-I (5 nM) for 24 hour 
(signaling, left) and 5 days (monolayer proliferation, right). E. MCF-7 cells infected with scrambled or Nrf2-targeted 
shRNAs were starved and treated with IGF-I (5 nM) for anchorage independent soft agar assay analysis. qRT-PCR data 
were normalized to RPLP0 housekeeper gene. Graphic data are mean ± SEM; results are representative of at least three 
independent triplicates experiments. 
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Figure 4.4 Nrf2 suppression resulted in redox upregulation, cellular reduced GSH downregulation, and 
mitochondrial function impairment in MDA-MB-231 cells. 
A. MDA-MB-231 cells were transfected with control or Nrf2-targeted siRNAs (25 nM) for 48 hours. Protein 
expression level of Nrf2 were assessed by immunoblotting. B. MDA-MB-231 cells were transfected with control, or 
Nrf2 targeted siRNAs (25 nM) for 48 hours. mRNA expressions of PPP metabolic pathway related genes (left) and 
ROS pathway related genes (right) were quantified by qRT-PCR. C. MDA-MB-231 cells with indicated genetic 
manipulations were maintained in full growth media. Left: NFE2L2 and xCT mRNA expressions were assessed by 
qRT-PCR. Right: Indicated protein expressions were assessed by western blotting. D. Cellular ROS levels of MDA-
MB-231 cells with indicated genetic manipulations. Data were normalized by titer glo reading. E. Cellular reduced 
GSH levels of MDA-MB-231 cells with indicated genetic manipulations were measured and normalized to titer glo 
reading. F. Mitochondrial membrane potentials were measured by using microplate reader in MDA-MB-231 cells with 
indicated treatment. Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) served as an assay control. G. 
MDA-MB-231 cells infected with scrambled or Nrf2-targeted shRNAs were transfected with an inducible ARE-
responsive GFP reporter for 48 hours. Phase contrast and GFP images were captured by Leica microscopy. qRT-PCR 
data were normalized to RPLP0 housekeeper gene. Graphic data are mean ± SEM; results are representative of at least 
three independent triplicates experiments. 
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Figure 4.5 Suppression of Nrf2 inhibited the proliferation of MDA-MB-231 cells. 
A. MDA-MB-231 cells with indicated genetic manipulations were plated in 24-well plates. Monolayer cell growth 
were measured by MTT assay. B. Clonogenic assay of MDA-MB-231 with indicated genetic manipulations. C. MDA-
MB-231 cells infected with scrambled or Nrf2-targeted shRNAs were plated on-top of matrigel for 3-dimentional 
culture. D. MDA-MB-231 cells were infected with scrambled or Nrf2-targeted shRNAs. Cells were fixed then stained 
with propidum iodide. Cell cycle frequencies were determined by flow cytometry. Graphic data are mean ± SEM; 
results are representative of at least three independent triplicates experiments. 
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Figure 4.6 Loss of Nrf2 sensitized MDA-MB-231 cells’ response to irradiation. 
MDA-MB-231 cells infected with scrambled or Nrf2-targeted shRNAs were treated with increasing dosage of 
irradiation then cell proliferation was analyzed by clonogenic assay (A), MTT monolayer growth (B), and anchorage-
independent growth (C). D. MDA-MB-231 cells with indicated genetic manipulations were treat with or without H2O2 
(10 µM). Cell surface CD makers were analyzed by flow cytometry. Graphic data are mean ± SEM; results are 
representative of at least three independent triplicates experiments. 
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Figure 4.7 Loss of Nrf2 reduced EMT in MDA-MB-231 cells. 
A. Phase-contrast images for cell morphology were captured by Leica microscopy. B. Indicated MDA-MB-231 cells 
were treated with or without IGF-I (5 nM). Cell migration potential was evaluated by boyden chamber assay. C. 
Indicated protein levels were assessed by immunoblotting in cells with indicated genetic manuniplations. D. mRNA 
expression levels of EMT makers were quantified by qRT-PCR in MDA-MB-231 cells with indicated genetic 
manipulations. qRT-PCR data were normalized to RPLP0 housekeeper gene. Graphic data are mean ± SEM; results are 
representative of at least three independent triplicates experiments. 
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Figure 4.8 Effects of siRNA downregulation of Nrf2 in T47D cells. 
A. T47D cells were transfected with or without control or Nrf2-targeted siRNAs (25 nM) for 48 hours. Protein 
expressions level of Nrf2 and xCT were quantified by immunoblotting. B. T47D cells were transfected with control or 
Nrf2 siRNAs (25 nM) for 48 hours. mRNA expressions of PPP metabolic pathway related genes (left) and ROS 
pathway related genes (right) were quantified by qRT-PCR. qRT-PCR data were normalized to RPLP0 housekeeper 
gene. Graphic data are mean ± SEM; results are representative of at least three independent triplicates experiments. 
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Figure 4.9 IGF-I did not stimulate Nrf2 expression in MDA-MB-231 cells. 
A. MDA-MB-231 cells with indicated genetic manipulations were serum starved then treated with IGF-I (5 nM) for 24 
hours. Protein levels of total Nrf2, phospho-Nrf2, phospho-AMPKα, phospho-p38MAPK, and actin were measured by 
immunoblotting. 
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Figure 4.10 Chemical inhibition of Nrf2 using all trans retinoic acid A (ATRA) resulted in ROS upregulation, 
AMPKα  activation, and growth inhibition in MDA-MB-231 cells. 
A. MDA-MB-231 cells were treated with indicated dosage of all trans retinoic acid or Nrf2-targeted siRNA (25 nM) 
then serum starved followed by IGF-I (5 nM) stimulation. Indicated protein levels were assessed by immunoblot. B. 
MDA-MB-231 cells were treated with increasing concentrations of ATRA. Cell monolayer growth was measured by 
MTT assay. Graphic data are mean ± SEM; results are representative of at least three independent triplicates 
experiments. 
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Figure 4.11 Nrf2 suppression resulted in ROS upregulation and growth inhibition in MDA-MB-436 cells. 
MDA-MB-436 cells were transfected with control or Nrf2 siRNAs (25 nM) for 48 hours. A. Protein expression of Nrf2 
and xCT were assessed by immunoblotting. B. mRNA expressions of PPP metabolic pathway related genes (left) and 
ROS pathway related genes (right) were quantified by qRT-PCR. C. Intracellular ROS levels were measured and 
normalized to titer glo reading in MDA-MB-436 cells with indicated genetic manipulations. D. Monolayer cell growth 
was analyzed in MDA-MB-436 cells infected with scrambled or Nrf2-targeted shRNAs. qRT-PCR data were 
normalized to RPLP0 housekeeper gene. Graphic data are mean ± SEM; results are representative of at least three 
independent triplicates experiments. 
 





Figure 4.12 Overexpression of xCT rescued CD44+/24- population in Nrf2 downregulated cells. 
MDA-MB-231 cells with indicated genetic manipulations were treat with or without H2O2 (10 µM). Cell surface CD 
makers were analyzed by flow cytometry. 
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Figure 4.13 Tamoxifen resistant cells expressed less Nrf2, exhibited higher level of cellular ROS, and were more 
sensitive to irradiation. 
A. mRNA expressions of NFE2L2 mRNA and ROS related genes were analyzed by qRT-PCR. B. Indicated cellular 
protein expressions were assessed by immunoblotting. C. Indicated cell lines were irradiated at an increasing dosage. 
Anchorage independent growth was determined by colonies formation in agarose after 14 days. Data are mean ± SEM; 
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Figure 4.14 Effects of Nrf2 suppression on amino acid metabolism. 
Concentrations of 20 amino acids were measured by University of Michigan Metabolomic Core. Concentrations were 
further normalized by total protein amount per sample. Graphic data are mean ± SEM; results are representative of at 
least three independent triplicates experiments. 
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Table 4.1 Loss of Nrf2 redirected cell metabolism from PPP to glycolysis. 
Contents in glycolysis, TCA, and nucleolide were measured by University of Michigan Metabolomic Core. Data 
presented as folder change. 
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The first part of the thesis emphasizes the therapeutic potential of downregulating 
IRS proteins by NT157.  NT157 was studied as mono- and combination therapy in 
various breast cancer models. In addition, we, for the first time, reveal that NT157 also 
targeted ERα in ERα+ breast cancer cells. Targeting IRS protein could be useful alone or 
in combination with other therapies in many different subtypes of breast cancer. Further 
work needs to be performed to evaluate growth inhibitory effects of NT157 compound in 
breast cancer xenograft models. The compound itself also needs to be modified to 
improve potency. 
 
The data presented in the third chapter of the thesis reveals that IGF-I regulates 
oxidative stress and thereby promotes proliferation by stimulating xC- transporter 
function in an IRS-1 dependent mechanism. xC- transporter expression level could be a 
promising biomarker to indicate tumor metabolic status to oxidative stress. xC- 
transporter could also be a target to enhance anti-IGF-IR therapy, chemotherapy, and 
radiotherapy in multiple subtypes of breast cancer.  
 
Our ongoing research also observed that IGF-I stimulated the message, protein, and 
cell surface expressions of heavy chain of the xC- transporter (CD98hc) in ER positive 
breast cancer cells (Figure 5.1). CD98hc has been reported to mediate β-intergin 
signaling [165], cell adhesion [166], and cell proliferation [167] in various cancers. 
CD98hc also forms L-type amino acid transporter-1 (LAT1) with the light chain SLC7A5 
[168, 169]. Interestingly, in our preliminary experiments IGF-I also regulated of SLC7A5 
gene expression. Cellular uptake of neutral branched amino acids through LAT1 has been 
reported to stimulate mammalian target of rapamycin (mTOR) in cancer cells [170]. Both 
CD98hc and SLC7A5 expression has been included in an immunohistochemical predictor 
of breast cancer outcome [171, 172].  It will be worthy and interesting to further study the 
roles of CD98hc and SLC7A5 in mediating IGF-I regulated cancer behaviors.  
 
Efforts have been made to treat human gliomas and lymphomas by inhibiting xC- 
function with the FDA approved drug SASP [173].  However due to the low potency and 
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metabolic instability (SASP is designed to be metabolized by azoreductases to 
sulfapyridine and 5-aminosalicylic acid, which do not have xC- inhibitory activities [174]) 
of the drug in vivo, those studies results were disappointing. To date, the structural basis 
of SASP interaction with xC- remains unsolved. It is insoluble in aqueous solutions and 
needs further modification to characterize the interaction with xC- [175]. Besides xC-, 
other pathways could be targeted to inhibit amino acid uptake. Glutaminase generates 
cellular glutamate from glutamine and its inhibition is an indirect target for inhibiting xC- 
transporter as xC- requires intracellular glutamate concentration for exchange of 
extracellular cysteine (Figure 5.1). Studies have shown evidences that targeting 
glutaminase by the inhibitor CB-968, CB-839, (Calithera Biosicences), and BPTES 
(Sigma-Aldrich) significantly suppressed TNBC tumor growth [176]. Another group also 
reported that the small molecule erastin is a potent selective inhibitor of xC- [177, 178]. 
Recent work from our and other laboratories suggest that xC- transporter is a compelling 
drug target either alone or in combination with IGF-IR targeted therapy, radio-, or 
chemotherapy in treating a broad spectrum of breast cancers.  These findings suggest a 
new direction for rapid drug development as well as research direction to characterize the 
importance of amino acid transport on cancer cell behaviors in cancer. 
 
The last part of this thesis investigates Nrf2 as a mono- or adjuvant therapeutic 
target in ER+, tamoxifen resistant, and TNBC/basal-like breast cancer subtypes. Nrf2 is a 
direct regulator of xCT gene expression. Our data suggest IGF signaling also controls 
Nrf2 expression and function in ER+ breast cancer cells. Consistent with the regulation 
of IGF-I on xCT mRNA expression, PI3K-AKT signaling also positively regulates Nrf2 
expression and function, which further emphasizes PI3K inhibitors’ value in cancer 
treatment. Nrf2 controls cellular redox status via metabolic reprogramming to generate 
NADPH and directly regulate of GSH biosynthesis, thereby promotes tumor growth, 
maintains stem cell population, and contributing to radio-resistance. Future investigation 
directed toward understanding the crosstalk between Nrf2 and cellular amino acid 
metabolism will help to reveal hidden function of this powerful molecule. On the other 
hand, accumulation of Nrf2 in TNBC/basal-like breast cancer cells may due to 
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inactivation of Nrf2 inhibitory molecule Keap1. Sequencing for Keap1 loss-of-function 
mutation could help to predict prognosis and also stratify patients for ROS-manipulating 
therapies. 
 
Although preclinical evidence provides strong rationale for clinically targeting 
IGF/insulin signaling, the withdrawal of figitumumab from phase III clinical trials raised 
significant concerns about the clinical utility of targeting IGF-IR with a monoclonal 
antibody.  However, we still believe that IGF-IR antibodies can be clinically beneficial in 
a subset of breast cancer patients through the use of appropriate predictive biomarkers 
and adjuvant therapies, and coupled with cautious monitoring of insulin levels during the 
therapy. Other drugs affecting IGF/insulin signaling such as TKIs, ligand neutralizers, 
and mTOR inhibitors show promise, most likely in combination with conventional and 
novel agents. A more insightful understanding of IGF/insulin system and its crosstalk 
with other critical signaling pathways in breast cancer cells is needed to optimize the 
targeting of the IGF/insulin system in breast cancer.  
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Figure 5.1 Schematic diagram showing the function and regulation of the plasma membrane cystine-glutamate 
transporter xC-.  
The transporter is composed of two subunits linked by a disulfide bond: CD98hc serves as anchorage to the plasma 
membrane; xCT is the functional subunit imports cystine into cell while exporting glutamate to the extracellular 
environment with a stoichiometry of 1:1. In TNBC cells, CD44v stabilizes xCT membrane expression and therefore 
facilitates the uptake of cystine to generate intracellular GSH. GSH further reduces cellular redox and sequentially 
promotes cell proliferation. In ER positive breast cancer cells, growth factors such as IGF-I, IGF-II, and insulin 
stimulate xCT and CD98hc mRNA and protein expression through IGF-I receptors and IRS-1 protein. The up-regulated 
plasma membrane expression of xC- transporters ultimately promotes cancer cell proliferation.  The negative regulation 
of xC- transporter function could be achieved by direct inhibition with sulfazalazine and erastin or indirect suppression 
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